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Abstract 
Acceptance-based Intervention for HIV Medication Adherence 
Ethan Moitra 
James D. Herbert, Ph.D. and Evan M. Forman, Ph.D. 
 
 
 
Human immunodeficiency virus (HIV) is a global health concern.  Although effective 
pharmacological treatments, such as highly active antiretroviral therapy (HAART) have 
been developed and implemented, a significant number of adults with HIV in the U.S. do 
not maintain adherence at adequate levels for treatment to work.  The data suggest HIV 
medications should be taken 90% of the time or more, though typically Americans with 
HIV take their medications 60% to 70% of the time.  Although some promising results 
have been shown using traditional cognitive-behavior therapies, an acceptance-based 
approach to HAART adherence may be preferable in this population because of the 
significant role played by denial.  We compared treatment-as-usual to treatment-as-usual 
plus an acceptance-based intervention for increasing HAART adherence in a 
predominantly minority, low socio-economic status sample of 31 uninsured adults in a 
large metropolitan community primary care clinic.  Results revealed no differences in the 
interventions on self-rated measures of adherence.  However, patients in the acceptance-
based group showed greater improvements in CD4 level gains over time relative to those 
who received treatment-as-usual.  Secondary analyses revealed that baseline anxiety and 
baseline mindful acceptance predicted adherence at follow-up.  These data suggest that 
acceptance-based strategies are promising tools for increasing adherence to HAART 
among HIV-positive persons.  Future studies with larger samples are needed to expand 
upon these results, including adapting the intervention to an individual treatment format. 
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CHAPTER 1: INTRODUCTION 
Human immunodeficiency virus (HIV) is a global health concern.  In the U.S., 
rates of infection continue to rise in certain populations.  HIV’s chronicity requires a 
lifelong vigilance to healthy living and safe practices.  The challenge of living with HIV 
involves long-term, complex self-management by patients as well as required medical 
care and typically, supportive social services.  Maintaining treatment requires education, 
motivation, and effective problem-solving skills.  Extant literature has focused on general 
variables that may affect adherence to HIV treatment, and some empirical support for the 
efficacy of interventions promoting adherence has been documented.  However, no “gold 
standard” treatment has been achieved and it is unclear whether a standard protocol will 
emerge given the substantial differences among patients’ individual needs.  The 
following sections describe these obstacles to good HIV care, and introduce a novel 
intervention designed to address the complex needs of this population. 
1.1. Management of HIV 
1.1.1. Overview 
 
Approximately one million people or more in the United States have HIV/AIDS 
infection (Schneider, Glynn, Kajese, & McKenna, 2006), and up to 27% of those infected 
are unaware of their diagnosis.  AIDS diagnoses among African-American and Latino 
populations, and particularly among women, are rising, suggesting risk varies across 
groups.  Factors influencing this variability include racial and sexual characteristics.  For 
example, men who have sex with men (MSM) account for a majority of the HIV 
infections in adult men in the U.S. (Centers for Disease Control (CDC), 2007).  
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Additionally, African-American MSM show double the rates of infection compared to 
their Caucasian counterparts (CDC, 2005). 
1.1.2. Pharmacological treatment 
Most people require medications for effective HIV management.  Highly active 
antiretroviral therapy (HAART), introduced in 1996, has demonstrated significant 
success in inhibiting HIV viral replication.  Furthermore, its benefits include reductions 
in morbidity, mortality, and overall health care costs for HIV-positive persons (Crum et 
al., 2006; Mocroft et al., 2003).  However, adherence to HAART regimens is of 
paramount importance for treatment to be effective and to prevent the development of 
treatment-resistant virus, as well as to minimize the likelihood of passing treatment 
resistant virus to another person.  HIV’s short half-life allows it to mutate and replicate 
quickly (Deeks, Smith, Holodniy, & Kahn, 1998).  To be effective, it has been estimated 
that adherence in taking antiretrovirals must approach 90% (Bansberg et al., 2001), a very 
high rate for any medical treatment.  Adherence, in this context, can be defined as the 
percentage of time, in a given time span, that an individual takes his or her medications 
when he or she is instructed to, according to physician recommendations. 
The goal of HAART is to reduce the level of HIV, as measured by viral load, in 
the bloodstream to undetectable levels. Self-reported adherence has been shown to be 
reliably associated with viral load as well as CD4 counts, a form of T-helper cells 
affected by HIV (Simoni et al., 2006a), and is often used as a proxy for how well these 
goals are being accomplished.  Although no consensus has been reached, it appears 
changes in adherence can be reflected in these biologic measures almost immediately.  In 
a study examining the effects of adherence to a HAART regimen on viral load and CD4 
 3 
cell counts, Gross and colleagues (2001) found that participants who reached 
undetectable viral loads were maintained at a median range of adherence of 93%; those 
participants who did not achieve undetectable viral loads demonstrated a median range of 
adherence of 70%.  Notably, the investigators found no significant differences in 
adherence until the second month of therapy; this suggests that most people are able to 
maintain adequate levels of adherence early in treatment and that the crux is maintenance.  
Furthermore, rates of adherence to a person’s first antiretroviral regimen may be related 
to later adherence and virologic control (Cingolani, Antinori, Rizzo, et al., 2002).  
Therefore, intervention might be needed most for those who have struggled with 
adherence not only initially, but at later time points as lifelong maintenance is crucial for 
survival. 
1.1.3. Adherence to HIV treatments 
Despite the risks previously noted, adherence in the U.S. to HAART remains low; 
most researchers estimate median adherence to be 60% to 70% (Bartlett, 2002).  Non-
adherence to antiretrovirals has somewhat more dire consequences than non-adherence to 
other types of medication.  Resistance develops relatively quickly in patients who have 
even brief gaps in adherence.  Furthermore, because some medications (particularly those 
in the same class) share similar resistance profiles, cross-resistance can occur, eliminating 
the future use of drugs from an entire class. Another concern is the ability of persons with 
treatment resistant HIV to pass resistant virus to another person, thereby limiting the 
second party’s treatment options early in the course of the infection (Kelly, Otto-Salaj, 
Sikkema, Pinkerton, & Bloom, 1998).  
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Although newer HIV regimens might be easier to adhere to given the advent of 
combination medicines and once or twice daily dosing regimens, it is common for people 
with HIV to require multiple medications, either to treat opportunistic infections, co-
morbid health conditions, or to enhance the effects of antiretrovirals (Kelly et al., 1998).  
Not surprisingly, more complex regimens are associated with decreased compliance 
(Haynes, 1974), and this added burden contributes to patients’ difficulties with 
adherence. 
1.1.4 Summary and conclusions 
 HIV remains a significant health concern in the U.S., with infections holding 
steady and/or rising in a variety of populations.  Although effective pharmacological 
treatments, such as HAART, have been developed and implemented, a significant 
number of adults with HIV in the U.S. do not maintain adherence at adequate levels for 
treatment to work.  The data suggest that efficacy requires adherence levels at 90% or 
higher, though typically Americans with HIV take their medications 60% to 70% of the 
time.  Research into mediating factors and interventions designed to promote adherence, 
particularly in individuals struggling with medication adherence at late-out time points, is 
vital to effective HAART. 
1.2. Factors affecting adherence 
1.2.1. Overview 
A significant amount of research has been conducted on variables that predict 
non-adherence to HIV treatments in the general population.  Ickovics and Meisler (1997) 
identified five categories of variables associated with poor medication adherence in 
individuals with HIV (see Table 1).  According to these authors, poor adherence is 
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associated with diminished perception of benefit, low adherence intent, greater perceived 
cost-to-benefit, and poor social support.  Negative environmental factors such as poor 
relationship between patient and provider, coupled with negative clinic attributes lead to 
poor adherence.  Lastly, individuals with relatively good health (e.g., low viral load) are 
less likely to maintain adequate adherence, suggesting the immediacy of acute illness can 
promote positive behavior.  The complexity of this model can be burdensome, as it 
suggests health care providers must consider, and ideally influence, a wide variety of 
variables.  Inevitably, manipulation of variables such as HIV severity, clinical setting, 
and treatment regimen is limited or impossible, and providers must focus on effectiveness 
given their real-world constraints. 
1.2.2. Measuring adherence  
Existing literature has used several means to assess adherence, including direct 
(biological assays) and indirect (self-report, collateral reports, pharmacy refill data, and 
Medication Event Monitoring Systems (MEMS)) measures. There is some debate as to 
what constitutes the “gold standard” (Simoni et al., 2006a); consequently, multi-modal 
methods combining biological assays, self-report, and MEMS or pharmacy data are most 
frequently used. The use of MEMS technology and direct observation (i.e., the provider 
watching the patient take the medications in the clinic) may be more robust, but can be 
cost prohibitive, and difficult to implement (Ickovics & Meisler, 1997).  
Self-report measures of adherence address the issues of cost and ease of 
administration. However, adherence can be difficult to quantify with self-report, due to 
concerns about social desirability (Arnsten et al., 2002), inaccurate or incomplete 
memories of medication taking, and other biases associated with self-report measures. 
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For example, there is some evidence to suggest that self-report measures provide inflated 
measures of actual adherence (when concurrently assessed by MEMS; Arnsten et al., 
2001). Conversely, there is evidence to suggest that self-report is a meaningful tool for 
measuring adherence. According to a meta-analysis by Simoni and colleagues (2006b), 
self-report measures of adherence (especially those that use small recall periods) were 
associated (using odds ratios and correlations) with measures of viral load in 84% of 
recall periods, as well as highly correlated with data collected through MEMS or similar 
technology.  These authors suggest supplementing self-report measures of adherence with 
pharmacy refill data or biological assays. 
1.2.3. Low socioeconomic status 
 SES is inversely correlated with HIV medication adherence (CDC, 2005).  
Researchers hypothesize this relationship is best explained by associations between low 
SES and other variables that can result from financial challenges and poverty, including 
lack of life stability due to unemployment or homelessness; lack of access to healthcare; 
and lack of resources to store medications (e.g., some HAART medications require 
refrigeration) (Ickovics & Meisler 1997).  Although individuals of low SES status are 
particularly vulnerable to HIV infection (CDC, 2007) and at risk for poor adherence, 
interventions targeting these individuals are sparse.  This may be due to logistical 
impediments such as lack of transportation, which ultimately leads to high attrition rates 
(Mellins et al., 2003).  Consequently, the present study targeted this population because it 
is in particular need of easily accessible, short-term assistance. 
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1.2.4. Dominant models of health behavior 
Psychological variables in the context of HIV medication adherence are important 
because they can affect an individual’s behavior, particularly in the context of cognitive 
variables like appraisal.  The cognitive appraisal model of stress and coping as a 
comprehensive theory to explain individual differences in response to stress was first 
described by Lazarus (1966), and was later expanded by Lazarus and Folkman (1984). 
The model has received a great deal of attention from researchers in explaining various 
aspects of chronic illness. The model, according to Lazarus and Folkman (1984), assumes 
that when confronted with a particular stressor, such as an HIV diagnosis, people will 
respond in various ways. How one perceives an event, feels about it, and synthesizes it 
with their motivational beliefs will influence his or her response.  
The primary appraisal process requires individuals to evaluate whether a 
particular event has the potential to jeopardize their wellness, when and how this process 
could occur, and if there is anything that can be done to alter the course of potential 
consequences. Based on the answers to these questions, an event may be considered 
irrelevant, benign / positive, or stressful. A “benign / positive” event is one that could 
sustain or further develop wellness. If the event is perceived as stressful, the event is then 
characterized into one of three categories of stress: harm / loss, threat, or challenge. Most 
events that are not perceived as irrelevant (even positive events) are associated with some 
degree of stress. 
In many instances, the mere presentation of a particular event may result in a 
harm / loss appraisal. This is particularly true in the case of being diagnosed with HIV; 
appraisal of the diagnosis itself is subjective, such that a person may perceive that some 
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harm or loss has already occurred, or has the potential to occur in the future. 
Alternatively, a diagnosis of HIV could be perceived as a challenge, such as an 
opportunity for growth and to take control of one’s overall health. Challenges are 
associated with positive affect. However, the appraisal process is fluid, and the nature of 
the stressful appraisal can change over time, as a person develops evidence of their ability 
to confront stressors or becomes aware of new information. Lazarus and Folkman suggest 
that the experience of perceiving a stressful event as a challenge versus a threat has 
implications for emotional development, and successfully navigating a challenging 
situation (or successfully confronting misfortune) can result in a healthier emotional state 
overall.  One connection these authors fail to explicitly make is between navigating a 
challenging situation and personal goals and values.  Goals can be defined as measurable 
aims a person outlines: things that can be accomplished or not accomplished.  Values are 
broader pursuits that cannot be fully completed as they reflect what is important to a 
person and require ongoing vigilance.  Goals help the individual work towards values.  
Clearly, goals and values must play an important role in fostering individual willingness 
to directly confront a problem like HIV diagnosis rather than avoid it.  We will return to a 
discussion of personal values and goals below. 
The secondary appraisal process involves an examination of one’s resources with 
which they can confront a situation. A person is forced to evaluate possible solutions, 
their potential effectiveness, and their perceived ability to carry out any potential 
solution. Lazarus and Folkman suggest that a challenge appraisal is more likely to occur 
when a person has a higher sense of control over the outcome.  Despite their names, there 
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is not specified order in which the primary and secondary appraisal occur; rather, they 
work simultaneously to shape the appraisal of a situation.  
Beliefs play an important role in the appraisal process, especially beliefs about 
control.  Because of HIV’s notoriety, most patients likely have preconceived notions 
about the disease process, its prognosis, and treatment options.   For example, if a woman 
with HIV believes that she can prevent her health from worsening, she may be more 
likely to act in ways consistent with that belief, such as adhering to her HAART regimen. 
Conversely, if this woman does not believe that she can control the outcome of her 
future, she may be less likely to engage in these preventative behaviors. If a woman is 
unfamiliar with this information, her beliefs may depend largely on information obtained 
from her physician. This may be especially true if there are high costs to control (such as 
the negative side effects associated with HAART regimens).  Not surprisingly, this 
relationship between beliefs and adherence promotion has taken hold in most models of 
adherence intervention, particularly those that seek to foster motivation via 
psychoeducation and motivational interviewing techniques.  Certainly, healthcare 
providers must also consider patients’ social supports as important factors in this model. 
Other similar models have been developed in order to further explain the role of 
beliefs in health related behaviors. One such model is the Health Belief Model (HBM), a 
social cognition model of behavior that was developed by Rosenstock (1974) in order to 
clarify why people did not actively engage in activities to prevent disease, despite the 
availability of technology and information to do so. The model posits that in order for 
individuals to engage in a heath related behavior, they must consider their personal 
beliefs about the potential threat caused by a particular disease, as well as the perceived 
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benefits and costs of a specific course of action.  According to the model, an action is 
more likely if the perceived threat is high enough to outweigh any risks or barriers to the 
specified action. More specifically, individuals are more likely to engage in a particular 
health behavior when they perceive that the risks of not engaging in that behavior carry 
with them serious ramifications, both socially and physically (Becker, 1974). It has also 
been suggested that changes in medication adherence patterns may lead to changes in 
beliefs (Haynes, 1974).  According to research by Taylor and colleagues (2000), positive 
beliefs about one’s self-efficacy in response to HIV diagnosis lead to not only improved 
mental health, but improved disease self-management. 
 The HBM gained popularity in research attempting to explain adherence to 
treatments for chronic illnesses, such as cardiovascular disease, hypertension, and 
diabetes in the early 1980s, and health beliefs have been implicated in poor adherence 
(Haynes, 1974).  More recent research has begun to investigate the role of the HBM in 
adherence to HIV medications.  For instance Malcolm et al. (2003), examined the role of 
beliefs in individuals with excellent HAART adherence records.  Notable patterns voiced 
by these participants included they consistently believed adherence rates needed to be 90-
100% for medication efficacy, they were open about their HIV status and received 
substantial social support, and they cited staying healthy as their key motivator.  These 
results suggest beliefs can be an important variable inciting healthy medication adherence 
behavior. 
 These cognitive models of healthy behavior have important implications for 
adherence interventions.  For instance, clearly psychoeducation on the effects of HAART 
is important.  However, as noted above, these models do not directly address the role of 
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values in guiding beliefs.  For instance, what was the underlying aim in staying healthy 
for participants in Malcolm and colleagues’ (2003) study?  For example, for some 
participants it may not have been simply staying healthy for the sake of being healthy.  
Instead, being healthy may have meant something more to participants, such as it could 
lead to a longer life in which they would have more opportunities to fulfill life goals.  In 
addition, individual differences in health-related values may be important to assess, 
especially in the context of developing targeted interventions. 
1.2.5. Thought suppression 
An important individual factor to consider is the meaning behind taking HIV 
medications: acceptance of the diagnosis and its related stresses.  Such acceptance 
requires a willingness to acknowledge the cause of infection, the implications of infection 
on the future, and openness to altering behaviors to fit the needs of maintaining healthy 
living.  Acceptance of infection is not easy and is linked to denial, or the need to repress 
the realities of living with HIV.  The intentional control of distressing cognitions and 
emotions related to HIV may be a significant variable affecting medication adherence.  
For instance, suppression of fear associated with HIV might lead to an unrealistic 
perception of one’s health, causing the person to be lackadaisical about adhering to his or 
her medication regimen.  Breuer and Freud (1895) initially commented on the pernicious 
effects of emotional suppression; this perspective has continued into the 21st century (see 
Hayes, Wilson, Gifford, Folette, & Strosahl, 1996, for a review).  Wegner and Zanakos 
(1994) found suppression of emotional thoughts magnified the emotionality and 
accompanying physiological reaction of the suppressed thoughts.  Further, it appears 
attempts at thought suppression exacerbate symptoms, producing a “rebound effect” in 
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which thought frequency increases (Clark, Ball, & Pape, 1991; Zeitlin, Netten, & Hodder, 
1995).  Research suggests suppression or control of private experiences as avoidance-
based coping styles produce poorer overall outcomes in the treatment of chronic diseases. 
Specifically, avoidance-based coping strategies do not appear to be protective 
with respect to the mental health of chronically ill populations, including persons with 
HIV.  Avoidance-based coping is associated with lower adherence (Amir et al., 1997) and 
higher levels of distress (Holohan & Moos, 1987; Thompson, Gil, Abrams, & Phillips, 
1992).  Weaver and colleagues (2005) assessed the degree to which coping style was 
associated with adherence to HAART among a sample of 322 HIV positive adults. 
Weaver and colleagues found that a higher degree of avoidance-oriented coping was 
associated with lower levels of adherence, while approach-oriented coping was not 
associated with adherence. 
In a study conducted by Jones and colleagues (2003), avoidance behaviors such as 
behavioral disengagement and self-blame were negatively correlated with adherence to 
HAART among a sample of 174 women. Interestingly, at least one study has 
demonstrated that women infected with HIV/AIDS are more likely to engage in avoidant 
coping strategies when compared to their male counterparts (Fleishman & Fogel, 1994). 
 Johnson and colleagues (2005) examined the effects of coping style on adherence, 
and how this relationship may be mediated by the experience of HAART associated side 
effects. A sample of 2,765 persons with HIV who were recruited to participate in the 
Healthy Living Project participated in this examination.  Participants who reported severe 
side effects were significantly less likely to achieve greater than or equal to 90% 
adherence.  Furthermore, adherence was particularly compromised in those participants 
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who reported medication side effects. This relationship is particularly important to 
understand, as most persons treated with HAART will experience at least minimal side 
effects, which may or may not resolve. This is in part because HAART regimens usually 
contain at least one protease inhibitor, which are associated with significant 
gastrointestinal side effects, such as nausea and diarrhea, and may cause symptoms of 
peripheral neuropathy (Williams, 1997). 
1.2.6. HIV and stigma 
In many instances, the mere experience of being diagnosed with HIV may lead to 
feelings of harm and loss.  Appraisal of the diagnosis, itself, depends on personal history 
too.  One aspect of this personal history is culturally patterned stigma-associated 
responses based on knowledge of infection and cause of infection; these variables can 
produce psychological pain as well (see Madru, 2005, for a review).  Widespread 
reactions of others in the community may be harsh, particularly in cases of disclosing 
drug use, high risk sexual behaviors, or homosexuality.  A lack of knowledge and 
understanding of the disease and its communicability can also lead to responses, such as, 
“you’re dying;” “you’re infectious;” and “stay away!”  Not surprisingly, fear of stigma 
has been associated with poor HIV medication adherence (Schuster et al., 2005).  Also, 
maintaining adherence to HIV medication is complicated by the implicit need for 
transparency despite fear of rejection and worry about others’ reactions in new 
environments and in new relationships. 
Typically, values affect a person’s appraisal of negative situations and subsequent 
action such that when something highly valued is threatened, a person’s appraisal will 
guide the person to beneficial action.  In this population, a fearful response to HIV 
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infection and its long-term implications could provide the impetus to strictly follow 
medication regimens.  However, we hypothesize value-inconsistent behavior is not 
uncommon in the HIV population.  Specifically, many individuals with HIV may behave 
in a way inconsistent with their values to avoid the psychological stress of accepting their 
HIV diagnosis and its related needs (i.e., strict adherence to medication).  Adequate 
adherence is further complicated by the fact that many individuals on HAART are 
asymptomatic and the payoff for adherence is delayed progression, a distal reinforcer for 
their positive behavior.  Examples of values among persons with HIV/AIDS could 
include a desire to have, and to maintain positive relationships with family and or/friends; 
a desire to be productive at work or home; and to live a spiritually-consistent life.  
Clearly, poor medication adherence would jeopardize these domains and therefore would 
be considered value-inconsistent.  Instead of targeting values, a person may respond to 
adversity by avoiding psychological pain.  Such attempts to regulate private experiences 
(e.g., bodily sensations, feelings, thoughts) have been termed “experiential avoidance” 
(Hayes, Strosahl, & Wilson, 1999). 
1.2.7. Summary and conclusions 
In summary, a variety of factors influence adherence to HAART regimens among 
patients with HIV/AIDS, ranging from individual to environmental factors.  Adherence is 
measured in a variety of ways.  Although self-report measurement has flaws, it remains 
an important and relatively reliable form of assessment as part of a multi-modal 
approach.  Low adherence is correlated with demographic variables such as SES and race 
and therefore warrants close attention.  Furthermore, cognitive health belief models 
emphasize the role of beliefs in promoting positive behaviors.  However, these 
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implications have not been extensively examined in the context of their relationship to 
broader factors such as life goals and values.  The existing literature suggests that 
avoidant coping styles have an adverse effect on adherence to HAART because they can 
often lead to denial.  A lack of acceptance of the diagnosis and its implications, in 
addition to ongoing fear of stigma and associated community reactions, limit the 
openness of many HIV/AIDS patients about their disease and its management.  Due to 
fear of stigmatization and judgment, many individuals avoid discussing their diagnosis 
and suppress thoughts associated with living with HIV.  In fact, thought suppression 
might serve to exacerbate symptoms and lead to poorer overall mental and physical 
health.  This may take the form of experiential avoidance, an individual’s attempts to 
control internal and external events in an effort to avoid psychic pain.  The present study 
confronted this coping strategy through the application of interventions designed to foster 
acceptance and mindfulness.  Such technologies contrast with previous interventions, 
most of which have focused primarily on cognitive behavioral therapies (CBT) that 
sought to change or even suppress thoughts regarding the disease and its implications. 
1.3. HAART adherence interventions 
1.3.1. Preliminary reviews 
 In the 1990s, medication adherence studies were scarce.  For instance, a Cochrane 
Review examining adherence interventions from January 1996 to April 1999 showed 
only one study that investigated HAART adherence empirically, with most studies 
focusing on feasibility (Haddad et al., 2000).  This is not surprising as early HIV 
medications were not particularly effective and relatively uninfluenced by adherence 
levels.  Fogarty et al. (2002) supplemented this review by expanding the scope of their 
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analysis to include conference abstracts and presentations, in addition to published 
papers.  They examined a mixture of three randomized controlled trials (RCTs), cohort 
studies, and numerous naturalistic observational studies.  Fitting drug schedules into daily 
routines and education targeting knowledge, recall, salience, and understanding were 
found to be important factors related to adherence.  Despite these important conclusions, 
these reviews were primarily qualitative in nature. 
A more recent review conducted by Côté and Godin (2005) examined the efficacy 
of extant adherence interventions, summarizing results from 16 intervention studies.  
Seven of the 16 studies were considered Phase I or II National Institutes of Health (NIH) 
studies, as they reported initial feasibility of pilot interventions and consequently, were 
quite small.  Notably, most did not include a control group.  Phase I studies examine 
initial safety and effects of interventions; Phase II studies investigate the effects of the 
intervention, including its mechanisms of action; and Phase III studies compare 
interventions to established care guidelines.  Nine studies were considered Phase III NIH 
studies, though only half had sufficient sample sizes.  None of these small impact studies 
showed significant, lasting effects; however, three of the four major clinical studies did.  
Safren and colleagues’ (2001) intervention provides an example of the prototypic major 
clinical trial.  Forty-nine adults who reported not taking their HIV medications during the 
past 2 weeks were randomized to either a control group, consisting of a pill diary and 
questionnaire only, or a single-session intervention using cognitive-behavioral techniques 
and motivational interviewing strategies in addition to pill diaries, followed by a 
telephone review one week later.  The cognitive techniques included teaching the patient 
to dispute his or her fears of early mortality.  Though both conditions showed 
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improvement in adherence (control: 9 percentage point increase; CBT: 20 percentage 
point increase), suggesting a pill diary elicited some positive effect, the active condition 
showed a faster rate of improvement (η2=0.08).  However, one-week changes are not 
clinically significant and assuming these changes carried over to long-term behavior 
change is presumptuous. 
Although no singular specific CBT protocol has been used predominantly with 
this population, most studies have employed a treatment package that includes several 
core elements, such as cognitive restructuring, cognitive disputation, and pill diaries.  
Another important variable to emerge from these reviews was measurement period: 
assessment at least 6 months post-treatment was more likely to show effect, rather than 
shorter follow-up.  Lastly, these reviews suggest intervention length (i.e., frequency of 
sessions, duration of sessions, etc.) does not influence outcome.  No overall differences 
were found between individual and group interventions, although data suggest individual 
treatment might be preferred (Martin et al., 2001), perhaps due to variables such as 
stigma avoidance. 
Unfortunately, comparisons among interventions examined in these reviews are 
hampered by the variability in the type of cognitive interventions used.  Not surprisingly, 
this variability impedes “real world” application because it remains unclear what aspects 
of the intervention produce effects.  Moreover, because numerous studies were pilot in 
nature and did not include a control group, the internal validity of their findings may be 
limited.  Most of these studies examined efficacy, with little attention paid to 
effectiveness because they did not examine extending interventions from the research 
domain to outpatient clinics.  Effectiveness is an important consideration as the field of 
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outcome research has been encouraged to specifically address the problems encountered 
by practicing clinicians, thus increasing the external validity of research (Seligman, 
1995).  Effectiveness research lends itself well to typical clinical settings, where 
healthcare providers encounter a wider range of patients than in a controlled study.  
Indeed, the effectiveness of treatment may be paramount as it reflects “real world” 
limitations such as restricted resources. 
1.3.2. Meta-analytic conclusions 
To date, two meta-analytic reviews have examined the efficacy of CBT-related 
treatments of HIV medication adherence.  Amico, Harman, and Johnson’s (2006) review 
examined results from 24 studies (RCTs and noncontrolled) published since the advent of 
HAART.  Inclusion criteria were: the research was published in a peer-reviewed journal, 
the intervention targeted adherence as a primary outcome, the intervention used a 
baseline or control group, and the published data afforded effect size calculations.  On 
average, a small-medium effect size of 0.35 was found in these interventions.  However, 
effect sizes for studies that intentionally recruited poor adherents were larger than those 
that did not (0.62 vs. 0.19, respectively).  Again, efficacy was not influenced by 
measurement procedures, intensity of intervention, or length of intervention.  These 
reviewers suggested the needs may vary between treatment-naïve individuals (i.e., those 
new to HAART and perhaps newly diagnosed) and others in interventions as well.  
Additionally, they note a majority of these studies did not examine adherence in people 
of racial minority status and/or low SES, a group particularly vulnerable to inadequate 
HAART adherence (CDC, 2007).   Finally, it should be noted that most of these studies 
focused on efficacy and thereby reduced their external validity by focusing on small, 
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homogenous samples, such as samples consisting primarily of men or incarcerated 
individuals. 
Simoni et al. (2006b) updated the previous meta-analysis through September 
2005, and focused solely on RCTs with the most rigorous methodology.  Nineteen RCTs 
were included; over half of which used individual interventions, 16% used a group 
format, and the rest used a mixture of both.  The modal number of sessions was 2 (range 
= 1-54).  A majority used CBT interventions, including discussion of cognitions and 
motivational interviewing techniques.  Odds ratios of the interventions producing 
significant effects compared to controls averaged 1.5, suggesting medium effects.  These 
authors noted more research is needed in the distribution of brief interventions 
appropriate for resource-limited settings, particularly among populations with complex 
needs and comorbid psychopathologies.  Indeed, they concluded that although many of 
the RCTs they examined were well designed, their interventions would be challenging to 
implement in actual HIV clinics, rather than research settings where motivation to 
participate and inclusion criteria were tightly controlled. 
1.3.3. Summary and conclusions 
 Adherence trials have been conducted since the advent of HAART in 1996, 
though their frequency has primarily proliferated in the past 5 to 7 years.  Qualitative 
reviews of early research in this domain note behavioral strategies, such as pill diaries, 
may be a useful intervention tool, in addition to cognitive and motivational techniques.  
Meta-analytic results suggest a medium to large effect size can be expected, particularly 
in studies of treatment refractory patients.  However, these conclusions are limited by 
their general focus on efficacy and lack of attention paid to external validity.  This is 
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particularly salient in HIV populations where factors such as patients’ low SES might 
impede treatment delivery because of transportation or childcare issues.  Generally, the 
effectiveness of adherence interventions has not been sufficiently investigated and 
warrants further attention.  This is a key factor in disseminating treatments as efficacy 
trials may produce variations in drop-out or participation rates.  Indeed, effective 
treatment must foster long-term motivation and address barriers to self-management.  
Therefore, the present study sought to incorporate important aspects of effectiveness 
trials, while retaining the necessary elements of efficacy research (e.g., manualized 
treatment and random assignment).  The present study used brief treatment that can be 
easily implemented in outpatient, primary care HIV settings.  Thus, this study combined 
elements from both research domains in a novel manner. 
1.4. Acceptance-based approach to HIV medication adherence 
1.4.1. Model of impact of emotional avoidance on HIV 
 A common reaction in people with HIV is to deny the realities of living with a 
chronic, potentially fatal disease (Willinger & Rice, 2003).  These realities include the 
unavoidable side effects of HAART medications, the stigma associated with disclosure, 
and potential pain associated with fear of the future.  Paradoxically, avoidance of the 
needs associated with disease management, in the form of denial due to low levels of 
acceptance probably exacerbates the condition.  The psychological avoidance of these 
stressors is termed experiential avoidance, as it suggests individuals with HIV attempt to 
avoid negative cognitions, feelings, and sensations through distraction and suppression 
strategies.  As a result of experiential avoidance, we suggest, medication adherence is 
avoided, as it requires acceptance of the diagnosis and ongoing health needs.  This leads 
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to a vicious cycle in which a person’s condition probably worsens, prompting even more 
experiential control. 
Therefore, interventions targeting experiential avoidance are warranted in this 
population because of the inherent need to accept, on some level, the responsibilities of 
living with HIV.  Current CBT interventions may not fully do this, as acceptance is not 
paramount in traditional cognitive models, and furthermore, many standard CBT 
programs teach patients to dispute cognitions that have some truth and are likely to 
resurface because of HIV’s chronicity.  However, it should be noted that simply 
experiencing these emotions might not be sufficient to ensure effective self-care behavior 
and effective HIV management must be promoted through education and behavioral 
strategies (see Figure 1). 
1.4.2. Acceptance and Commitment Therapy 
Acceptance and commitment therapy (ACT; Hayes et al., 1999) has emerged as 
one of the most widely practiced and researched of the new CBT treatments. ACT 
encourages patients to “defuse” from distressing psychological experiences and to adopt 
an accepting stance towards one’s experience as it unfolds in real time, while pursuing 
behavioral goals derived from personal life values.  Defusion is best described as the 
ability to view internal and external events neutrally, thereby limiting their emotional 
influence.  This contrasts traditional cognitive therapy, which is predicated on the 
assumption that therapeutic effects are mediated by changes in cognitions, including 
thoughts, beliefs, and schemas, and the corresponding emphasis on cognitive change 
efforts (Forman & Herbert, 2009).  ACT also stresses exercises aimed at identifying and 
crystallizing key personal values, translating these values into specific behavioral goals, 
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and designing and implementing behavior change strategies to realize those goals.  ACT 
promotes the concept of “committed action” as movement towards one’s goals in the 
context of experiential acceptance, thereby encouraging individuals to clarify and 
prioritize values in their lives.  In this population, a lack of commitment to values and 
goals might be instrumental in reducing medication adherence.  For instance, values of 
caring for oneself and one’s family would be compromised by avoidance of HIV self-
care.  Notably, ACT is postulated to influence outcomes by decreasing experiential 
avoidance (and thereby increasing experiential acceptance). 
The concept of experiential avoidance is derived from relational frame theory 
(RFT), a contextual theory of cognition and behavior (Hayes, Barnes-Holmes, & Roche, 
2001).  According to RFT, human behavior is largely directed by verbal rules learned 
early in life and continuously reinforced by the social-verbal community.  Language can 
be very useful in allowing humans to pass information from one generation to the next as 
well as affording a problem-solving technology.  However, language also permits the 
phenomenological experiencing of painful events that have never actually occurred, or 
that have occurred but are no longer present, as if they were psychologically present.  
Hence, experiential avoidance is often utilized in an effort to decrease the experience of 
psychological pain.  This has important implications for the treatment of individuals with 
HIV.  Specifically, RFT suggests that promoting experiential acceptance may reduce 
psychological distress; in HIV; this may take the form of increased acceptance of the 
diagnosis and prioritization of a value-driven life. 
As previously noted, experiential avoidance is often employed in an effort to 
decrease the experience of psychological pain.  The specific etiology of the pain is not 
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paramount, as all types of internal distress tend to elicit experiential avoidance; however, 
knowledge of typical sources of pain can be helpful in promoting an understanding of a 
particular population’s experiences.  In people with HIV, this might include fear of the 
future, anger at others, or worry about confessing to a past indiscretion.  These variables 
related to adherence because efforts are directed towards controlling these forms of 
distress, rather than towards healthy practices.  For example, clinical observations by the 
Principal Investigator have illustrated how some patients with HIV avoid taking their 
medication when in the company of loved ones who do not know about their diagnosis.  
Rather than facing the scrutiny of these family members and friends, patients would 
prefer not to take their medications.  Thus, they are willing to sacrifice long-term health 
benefits to avoid short-term awkwardness or pain.  From this perspective increased 
acceptance of HIV may take the form of acceptance of the diagnosis and associated 
realities such as cause of the infection, drug use history, the ongoing risk of negative 
reactions from others upon disclosure, etc.  Generally, acceptance of the diagnosis is a 
precondition to taking medication; acceptance of side effects is important too.  This 
perspective has been supported in the ACT-based literature, in other realms of research. 
Outcome research has demonstrated the efficacy of ACT interventions to treat a 
variety of maladies, including: the treatment of workplace stress (Bond & Bunce, 2003), 
psychosis (Bach & Hayes, 2002; Gaudiano & Herbert, 2006), depression (Zettle & 
Hayes, 1986; Zettle & Rains, 1989), test anxiety (Zettle, 2003), trichotillomania (Woods, 
Wetterneck & Flessner, 2006), epilepsy (Lundgren, 2004), obsessive compulsive disorder 
(Twohig et al., 2006), and social anxiety disorder (Dalrymple & Herbert, 2007).  
Additionally, ACT has demonstrated success with behavioral medicine applications 
 24 
including chronic pain (McCracken & Eccleston, 2006), cigarette smoking cessation 
(Gifford et al., 2004), Type 2 diabetes management (Gregg, Callaghan, Hayes, & Glenn-
Lawson, 2007), and substance abuse (Hayes et al., 2004; see Hayes, Luoma, Bond, 
Masuda & Lillis, 2006, for a review).  Lastly, experiential avoidance has been shown to 
be a mediator in several studies involving a range of psychopathology (Levin, Yadavaia, 
Hildebrandt, & Hayes, 2007). 
1.4.3. Summary and conclusions 
 Given the scope and thrust of ACT, an acceptance-based intervention lends itself 
well to the HIV population where experiential avoidance may be a mediating factor 
affecting medication adherence.  To the author’s knowledge, ACT has not yet been 
applied to this population.  Some suggest that mindfulness-based CBT may have specific 
advantages over disputation-based CBT (Teasdale et al., 2002).  For instance, building a 
therapeutic alliance with HIV positive patients is an important factor in promoting 
adherence and this lends itself well to ACT because the emphasis is not on disputing the 
literal truth of fears or worries, which can inadvertently alienate the patient.  Instead, 
patients practice experiential exercises to help them experience their thoughts as separate 
from external experiences.  ACT focuses on the workability (or unworkability) of 
behaviors that result from experiential avoidance, rather than the actual veracity of 
thoughts or feelings. 
The current study used established and psychometrically sound adherence and 
symptom measures.  Furthermore, the treatment was provided to a racially diverse and 
relatively low income sample.  Patients received an acceptance-based intervention 
program modeled on ACT, or treatment-as-usual (TAU).  To investigate real-world 
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effectiveness, treatment was delivered in a minimal number of sessions to a wide range of 
patients with minimal exclusion criteria, as it echoed the realities of primary care clinics 
such as scarcity of resources. 
1.5. Summary and study rationale 
 Until there is a curative treatment for HIV, understanding its management is of 
great importance. The advent of HAART in the mid-1990s represented a significant 
improvement in available treatment for people living with HIV.  Unfortunately, 
maximization of HAART’s benefits requires near-perfect adherence (Bansberg et al., 
2001), a challenge in any medical regimen.   Consequently, although advances in 
treatment have made HIV a manageable, chronic disease, for many patients, treatment 
success is not guaranteed. 
Research over the past decade has focused on variables affecting adherence and 
interventions designed to promote it.  The data suggest concurrent drug use, treatment 
setting, illness severity, and individual factors such as coping style, among others, are 
instrumental in predicting non-adherence (Ickovics & Meisler, 1997).  Avoidant coping 
appears to be particularly salient in this population because of the stigma associated with 
HIV and the implicit acceptance embedded in healthy disease management behaviors.  
Specifically, medication adherence is predicated on an individual’s acceptance of his/her 
diagnosis and a willingness to commit to long-term behavior change as a result.  This is 
particularly difficult in light of further challenges faced by individuals in low SES 
groups. 
The treatment literature suggests behaviorally-based strategies, in conjunction 
with cognitive strategies, produce some benefits.  However, no standard protocol, or for 
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that matter standard treatment length or intensity, has been established.  Additionally, the 
concept of experiential avoidance has not been investigated in this population.  This 
factor might be important as it has shown mediating effects in other health models, 
including the diabetes population (Gregg et al., 2007).  Thus, we employed a newer 
acceptance-based CBT intervention to address these questions. 
1.6. Statement of Purpose 
 The overall goal of the current study was to determine the effectiveness of ACT + 
TAU (labeled as “ACT” hereafter) compared to TAU for HIV medication non-adherent 
individuals.  Patients were randomized to ACT or TAU.  TAU consisted of 
psychoeducational services provided by primary care physicians, nurses, and case 
managers.  The ACT condition used patient education, goal setting, and mindfulness and 
acceptance-based techniques to promote medication adherence in addition to the TAU 
services.  The study was conducted within a multidisciplinary setting designed to 
integrate biological and psychosocial treatments. 
The specific aims of this study were to: 1) evaluate the efficacy of a newer 
psychosocial treatment in a controlled, longitudinal clinical trial of HIV medication 
adherence compared to standard treatment; 2) measure treatment outcome in a multi-
modal manner, including self-report and objective indices (i.e., viral load and CD4 
counts); 3) examine psychological factors (e.g., experiential avoidance) as potential 
predictors of treatment response; 4) examine the correlation between experiential 
avoidance and adherence; 5) examine the mediational effects of changes in experiential 
avoidance on medication adherence; and 6) integrate efficacy and effectiveness design 
elements to ensure applicability to typical clinical setting. 
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1.7. Hypotheses: Evaluating the effects of an acceptance-based intervention to 
promote HIV medication adherence 
Specific hypotheses for this study were: 1) participants in the ACT condition 
would demonstrate greater improvements in adherence outcomes compared to those 
receiving TAU only; 2) baseline experiential avoidance would be inversely correlated 
with medication adherence level; 3) baseline anxiety and depressive symptoms would be 
inversely correlated with medication adherence.  We aimed to evaluate the meditational 
effects of changes in experiential acceptance but were unable to do so because of the 
small sample size. 
CHAPTER 2: METHOD 
2.1. Participants 
 Participants were recruited from the Drexel University College of Medicine’s 
Partnership Comprehensive Care Clinic.  The Partnership is an integrative healthcare 
clinic developed in the 1990s to provide free, state-of-the-art services to uninsured 
individuals with HIV living in the Philadelphia community.  Specifically, we recruited 
patients from the Partnership’s primary care clinic who were having difficulties adhering 
to their treatment regimens and were not treatment naïve (i.e., they had not initiated 
medication use within the past month).  Referrals came from primary care providers, case 
managers, or self-referral from flyers posted in the clinic.  Patients with severe mental 
illness (i.e., active psychosis, schizophrenia) were not eligible for participation.  Also, 
patients with a documented diagnosis of mental retardation or AIDS dementia were not 
eligible.  Lastly, pregnant women were not eligible for participation.  Otherwise, all other 
patients who were fluent in English, could provide informed written consent, and could 
 28 
participate in psychotherapy were eligible in the present study.  Active substance abuse 
was not an exclusion criterion; however, it was assessed via patient charts and 
documented when present.  As remuneration for their participation, participants who 
completed all assessments, regardless of condition, were entered in a drawing to win a 
gift certificate of $100 at a popular store. 
2.2. Measures 
Self-report measures were used to assess demographic information, patient 
medication adherence, and psychological variables related to mood, anxiety, and 
experiential avoidance.  With patients’ written informed consent, medical charts were 
also reviewed to assess CD4 levels and viral load count.  These biological measures were 
taken within 10 days of initiation of treatment and within 2 weeks of follow-up 
assessments.  Self-report assessment took place at four time points: weeks 1 (i.e., 
baseline) and 3, and aimed to follow-up at 6- and 12-weeks (see Table 2 for planned 
assessment schedule).  However, it should be noted that in light of the multiple 
challenges participants in this study faced, follow-up occurred at less standardized time 
points and often occurred beyond 12-weeks post-enrollment (see Results section for 
further details). 
2.2.1. Pharmacy Refill Information.  After obtaining consent from participants, 
their pharmacy was contacted at each assessment point to determine what prescriptions 
were filled and how frequently this occurred. 
2.2.2. AIDS Clinical Trials Group Adherence Interview (ACTG AI; Chesney et al., 
2000). The ACTG AI was developed by the Outcomes Committee of ACTG to promote 
the use of reliable tools in clinical trials of persons with HIV.  It is one of the most widely 
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used instruments in the HIV/AIDS research field.  The ACTG AI consists of questions 
related to medication type, missing dosages, and reasons for missing dosages.  These 
reasons include simply forgetting to take the medication and not taking the medication 
because of its side effects.  Data suggest ACTG AI questions regarding missing dosages 
“yesterday,” “the day before yesterday,” “the past 4 days,” and “the past 2 weeks” 
correlated significantly and that missing dosages in the past 2 weeks had the highest 
factor loading on a single missing dosage factor (Safren et al., 2001).  Therefore, we 
calculated percentage of adherence using the number of dosages missed in the past 2 
weeks compared to number of prescribed dosages per week. 
2.2.3. Acceptance and Action Questionnaire-2 (AAQ-2; Hayes et al., 2004). The 
AAQ-2 is a 10-item measure written to assess an individual’s ability to accept 
undesirable internal events while otherwise continuing to pursue desired goals.  Items are 
rated on a 7-point Likert scale (1=never true, 7=always true).  Higher scores indicate less 
psychological acceptance.  This measure has adequate criterion-related, predictive, and 
convergent validities (Bond & Bunce, 2003).   
2.2.4. Beck Depression Inventory-II  (BDI-II; Beck at al., 1996).  The BDI-II is an 
extensively used and studied inventory designed to assess current severity of depression 
developed from clinical observations of depressed and non-depressed psychiatric 
patients.  Attitudes and symptoms consistent with depression are represented in a 21-item 
questionnaire, and patients are asked to rate the severity of each on an ordinal scale from 
0 to 3 (Katz et al., 1999).  The BDI-II is scored by summing the ratings, and cut-scores 
may be used to classify patients according to depression severity.  The BDI-II is based 
largely on the first edition of the BDI, which has indicated good reliability (r = .86 for 
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psychiatric patients, .81 for nonpsychiatric subjects) and strong content, concurrent, and 
discriminant validity in clinical and non-clinical samples (see Beck, Steer, & Garbin, 
1988, for a review). 
2.2.5. Beck Anxiety Inventory (BAI; Beck et al., 1988). The BAI is the most 
widely-used instrument for assessing anxious symptoms.  It is a self-report measure that 
reliably differentiates anxious from non-anxious groups in a variety of clinical 
populations as well as discriminates anxiety from depression.  The scale consists of 21 
items, including physiological and cognitive components, each describing a common 
symptom of anxiety (subjective, somatic, or panic-related).  Participants are asked to rate 
how much they have been bothered by each symptom over the past week on a 4-point 
scale ranging from 0 to 3.  The items are summed to obtain a total score that ranges from 
0 to 63.  The BAI has shown high internal consistency (α= .92) and has indicated good 
reliability and strong validity in clinical and non-clinical populations (Beck et al., 1988). 
2.2.6. The Philadelphia Mindfulness Scale (PHLMS; Cardaciotto et al., 2008) is a 
20-item self-report measure designed to assess mindfulness, defined as awareness that 
emerges through paying attention on purpose, in the present-moment, and non-
judgmentally to the unfolding of experience moment by moment.  These experiences can 
be internal (e.g., thoughts and feelings) and/or external (e.g., environmental sensations).  
The scale is further broken down into elements of present-moment awareness and 
nonjudgmental acceptance.  Items are rated on a 5-point Likert Scale (1=never, 5=very 
often) based on the frequency that subjects experienced the described item in the last 
week.  Higher total scores on the measure indicate greater mindfulness, although the 
authors recommend using the awareness and acceptance subscales independently, rather 
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than a total PHLMS score.  Odd numbered items measure levels of awareness and even 
items measure levels of acceptance.  Initial analyses of the PHLMS’s psychometric 
properties showed good reliability, internal validity, and concurrent validity (Cardaciotto 
et al., 2008). 
2.3. Treatments 
Block randomization was used to randomize participants to one of two conditions: 
treatment-as-usual (TAU) or an acceptance-based treatment condition plus treatment-as-
usual (ACT).  TAU consisted of standard clinic practices in response to medication non-
adherence, including provider education sessions, intervention consisting of supportive 
and motivational discussions from case managers, and verbal reminders given to patients 
at clinic appointments by providers and support staff.  TAU was implemented by primary 
care physicians and case managers, most of whom are licensed social workers.  TAU 
consisted of education regarding HAART and optimal adherence levels, in addition to 
some dialogue regarding barriers to adherence.  Providers were polled to assess length of 
TAU for participants in this condition.  TAU consisted of two or three 30-minute 
meetings with a healthcare provider and a case manager plus ongoing reminders 
whenever the participant returned to the clinic.   
The ACT condition consisted of TAU services as well as three to five weekly 60-
minute sessions conducted in a group format, with groups consisting of three to five 
patients, led by one of the primary investigators, who was a doctoral candidate in clinical 
psychology, trained and supervised by a licensed clinical psychologist with recognized 
expertise in ACT.  Healthcare providers were consulted for input and suggestions 
regarding the content and design of each session.  Each session served as a free-standing 
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intervention in which the overall acceptance-based principles were discussed and 
implemented (see Appendix A for treatment manual).  These core principles included 
developing “creative hopelessness” to highlight the unworkability of current emotional 
and behavioral control strategies, fostering a willingness to accept HIV-related distress, 
and directing patients towards clarifying and focusing on life values.  Treatment included 
experiential group exercises, role plays, and homework. 
As noted above, each session was free standing and participants could begin 
treatment at any session because the sessions were offered in successive weeks.  
However, an ideal course was deemed to consist of attending five sessions and was 
considered minimally complete via attendance of three sessions.  This design cannot rule-
out non-specific factors as variables affecting behavior because the active and TAU 
conditions were not completely matched for time.  However, by minimizing contact in 
the ACT condition, the intervention more closely mirrored that deployed in TAU.  
Finally, diffusion of treatment was minimized because of the relative brevity of the 
intervention in addition to the minimized patient-to-patient contact inherent in the clinic 
structure, where confidentiality is paramount.   
A meta-analytic review of randomized controlled trials for HIV medication 
adherence showed no evidence for moderating effects of treatment length (Simoni et al., 
2006b), suggesting the priority in designing this treatment would be its feasibility.  
Groups were offered in the late morning to accommodate individuals’ schedules.  
Furthermore, to adapt this to the clinic population, a small conference room in which a 
variety of clinic services are offered was used to facilitate group interaction. 
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2.3.1. Alternate designs considered 
 The present study compared an acceptance-based intervention (ACT) to a primary 
care clinic’s treatment-as-usual (TAU).  This design was chosen because the present 
project was pilot in nature and did not warrant more stringent controls of possible 
confounding variables.  Specifically, time was not be controlled for, suggesting it was 
possible for participants in the ACT condition to benefit solely because they received 
more time (i.e., attention) than those in TAU.  Additionally, those in the ACT condition 
could have showed changes in medication adherence simply because of expectancy 
effects.  Finally, receiving a group-based intervention altered the ACT participants’ 
treatment experience, differentiating them from those in TAU who received individual 
attention. It was deemed important first to explore if the brief ACT program would have 
any effect beyond TAU before investing resources in trying to dismantle such effects.   
2.4. Procedures 
 Potential candidates who met criteria for the study were referred by their case 
managers, primary care physician, or nurse.  Patients were approached by the Principal 
Investigator at the time of the next medical visit or contacted via telephone to determine 
their interest in the study after consultation with the referral source.  If patients agreed to 
participate, informed consent was obtained and demographic information was collected.  
Immediately following obtaining consent, participants were assigned a confidential 
identification number and completed self-report assessment measures.  Concurrently, 
they were randomly assigned to TAU or ACT.  One therapist conducted all sessions.  The 
primary care treatment team was consulted throughout patients’ participation in the study.  
If a patient appeared to develop an adverse reaction to treatment, the individual would 
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have been withdrawn from the study and provided standard care.  However, this did not 
occur during the course of the present investigation.  Data was collected at pre-treatment 
(i.e., baseline), then again at week 3, 6-week, and 12-week follow-ups. 
2.5. Statistical Analyses 
 2.5.1. Statistical Power.  Using the software G*Power 3 (Faul, Erdfelder, Lang, & 
Buchner, 2007), power was calculated for analysis of variance with an alpha set at .05 
and a medium effect size (f = .35).  This was chosen because both recent meta-analyses 
conducted comparing active interventions for HIV medication adherence to control 
groups reported medium to large effect size differences.   A sample size of 34 participants 
per group (total n = 68) would yield a power of .80, which Cohen (1988) designated as 
acceptable for behavioral research.  However, considering the multiple challenges most 
patients in this project faced, this project was underpowered.  A post-hoc power analysis 
was conducted based on 26 completers, a medium effect size (f = .35), and an alpha level 
of .05, resulting in power of .52.  To compensate for this and to minimize Type II error 
risk, effect sizes were examined, in addition to standard significance testing. 
Hierarchical linear modeling (HLM; Raudenbush & Bryk, 2002) was used to 
examine trends in change over time.  We chose this approach because HLM 
accommodates missing data in repeated measurement using empirical Bayesian 
estimates.  We first examined overall group trends regardless of condition, and then 
conducted analyses to examine if active treatment accounted for differential adherence 
change over time.  The data were hierarchically structured with 62 self-report 
assessments nested within 26 participants.  Coefficients representing assessment level 
were estimated for each person (level 1) and group differences in these coefficients were 
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estimated (level 2).  All models were random intercept models with a specified 
unstructured error covariance structure.  For our primary analyses, comparing ACT to 
TAU, total linear change (β11) consisted of three parameters: (1) linear change for 
individuals, with a condition value of 0 (i.e., TAU) (γ10); (2) linear change for 
individuals, with a condition value of 1 (i.e., ACT) (γ11); and (3) unexplained error (μ1).  
Effect sizes (Cohen’s d) were estimated using t statistics and their corresponding degrees 
of freedom derived from the HLM analyses.  There is currently no agreed upon method 
of estimating effect sizes in HLM; therefore, results should be interpreted with caution. 
2.5.2. Preliminary analyses.  An alpha level of .05 and one-tailed tests were used 
in the analyses unless otherwise specified.  A series of independent samples t-test and 
chi-square tests were conducted to compare groups on demographic variables and pre-
treatment symptoms and adherence levels to ensure random assignment resulted in 
relatively equal groups. 
2.5.3. Primary analyses. Primary analyses were conducted on treatment 
completers (i.e., attended at least 3 sessions).  To test the hypothesis that those receiving 
ACT would demonstrate improved outcomes compared to those receiving TAU only, 
continuous measures were analyzed via HLM. 
 2.5.4. Secondary analyses.  We expected relatively high treatment drop-out due to 
the population and its associated life challenges such as inadequate housing or 
transportation problems.  Therefore, HLM was used to examine trends in improvement 
regardless of incomplete data and regardless of number of sessions attended for those in 
the ACT condition.  This approach offers many desirable advantages compared to 
traditional intent-to-treat analyses that typically include last observation carried forward 
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(LOCF) analyses.  Specifically, HLM improves statistical power, provides insight into 
patterns of change, and does not assume the last observation is an unbiased estimate of 
end-of-treatment outcome. Furthermore, HLM permits measurement of individuals at 
different time points, which occurred in this study because of the participants’ 
complicated lives and associated difficulties completing questionnaire packets and 
presenting to clinic for biologic assessment. Effect sizes based on Cohen’s d statistic 
were computed as well.  Additionally, correlation analyses were conducted to determine 
if experiential acceptance, mindfulness, and measures of affective symptoms correlated 
with baseline adherence.  We used linear regression to assess the relationship between 
baseline measures and follow-up adherence levels.  Lastly, we planned to conduct 
meditational analyses using methods outlined by Krull and McKinnon (1999) but were 
unable to do so because of insufficient sample size. 
CHAPTER 3: RESULTS 
 All statistical analyses were conducted using SPSS statistical software, version 
17.0.  Because ideal sample size was not achieved, modifications to hypotheses were 
made, as described below. 
3.1. Sample description 
Figure 2 depicts a diagram showing participant assessment and recruitment flow.   
A total of 40 participants were referred.  A majority reported themselves to be self-
referrals (93%).  It is likely that some of these self-referred participants were encouraged 
to participate in the study by clinic staff, but were not formally referred via direct contact 
between clinic staff and study investigators.   Thirty-one met inclusion criteria and were 
willing to participate in the study.  Seven participants were excluded from participation 
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because they either were new to HAART (i.e., < 1 month) or were not on HAART at the 
time of recruitment; two did not consent to be enrolled in the study.  See Table 3 for a 
breakdown of demographic and study variables by condition at baseline.   Table 4 
presents study variables by condition at follow-up assessments. 
3.1.1. Demographic variables 
Average age of participants was 52 years (SD = 5.8), and 92.3% were male.  A 
majority of the sample was African American (84.6%), single (61.5%), and disabled 
(69.2%).  All participants’ income was below $15,000 per year.  The educational 
attainment of the sample was mixed as 30.8% completed 11 years of schooling or less, 
38.5% completed high school, and 30.8% completed at least some college.  Four 
participants (ACT=2, TAU=2) were homeless based on self-report of contact 
information. 
3.1.2. HIV variables 
Participants had been diagnosed with HIV for an average of 12.5 years (SD=5.2); 
18 of the participants had been diagnosed with AIDS, meaning their CD4 count had 
fallen below 200 at some point.  Forty-six percent acquired HIV through sex with men 
only, 30% via sex with men and women, and 23% via IV drug use.  Chart review 
suggested at least 8 participants had significant substance abuse histories (ACT=4, 
TAU=4).  However, no participants were actively using substances during the study 
(based on self-report, and to the best of the knowledge of clinic staff).  The participants’ 
average number of sexual partners in the past year was 4.8 (SD=6.6) and for those 22 in 
long-term relationships, 10 had HIV+ partners, 8 had HIV- partners, and 4 did not know 
their partner’s HIV status.  Six participants had been diagnosed with opportunistic 
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infections, such as Hepatitis C.  Only 1 participant had 1 HAART medication; all others 
had at least 2 HAART medications in their daily HIV management regimen.  The most 
complex consisted of 4 HAART medications.  The most common medications were 
Reyataz, Truvada, and Lexiva.  Based on chart review, one participant was being treated 
with Zoloft for mood/anxiety symptoms.  Self-reported HIV-related variables including 
time since diagnosis, CD4 count, viral load, and prescriptions were corroborated via chart 
review.  Review suggested participants were able to accurately report these data.  CD4 
was normally distributed but Viral Load was bimodal (see Figures 3 and 4 for graphical 
representation of baseline Viral Loads and CD4). 
Additionally, pharmacy refills were investigated via direct contact with 
pharmacies, following participant consent.  Results from pharmacies suggested 
participants were not delinquent in filling prescriptions at baseline.  It should be noted 
that at least 25% of participants received their medication refills directly from the study 
site.  Participants anecdotally noted that refills did not interfere with medication usage; 
instead, it was other variables that interfered with adherence.  The most commonly 
reported barriers to adherence among all participants were: being too busy (46.2%), not 
having access to pills (38.5%), side effects and other bad events related to the pills 
(36.5%), and stigmatization fears (30.8%). 
For these analyses, adherence was calculated as percent of pills taken for the past 
2 weeks using the ACTG AI questionnaire.  This is the standard method of assessing 
adherence via self-report (e.g., Safren et al., 2001).  Mean baseline adherence for 
participants in the ACT condition was 79.2% (SD=2.8) and for participants in the TAU 
condition it was 77.1% (SD=3.0). 
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3.2. Preliminary analyses 
3.2.1. Dropouts 
Four participants attended only one group intervention session.  The remaining 12 
participants attended at least 3 sessions and 4 participants attended all 5 sessions.  
Because there were so few treatment dropouts (n=4) in relation to treatment completers 
(n=12), statistical analyses could not be conducted to compare dropouts to completers on 
variables. 
3.2.2. Group equivalence through randomization 
To confirm randomization distributed participants equally between conditions, a 
series of t-tests and chi-square analyses were performed on baseline data.  Results 
suggested the ACT and TAU groups differed significantly in 3 domains: baseline 
experiential acceptance (t(24)=-3.55, p=.002), baseline anxiety symptoms (t(24)=2.58, p 
=.016), and baseline depressive symptoms (t(24)= 3.05, p=.006).  The TAU group had 
lower experiential acceptance and more severe anxiety and depressive symptoms.  
Independent samples t-tests showed the groups did not differ significantly in age, 
baseline mindfulness, time since HIV diagnosis, viral load, adherence, or CD4 count (p 
>.05).  Chi-square tests showed no significant differences between groups in race (p 
>.05).  However, the groups did differ in gender composition as the TAU condition did 
not have any females, whereas there were 2 women in the ACT condition (χ2(1)=5.80, 
p=.016). 
3.3. Primary analyses 
All predictor variables were centered to ensure the regression coefficient for each 
predictor variable was determined using the average value (i.e., mean=0) for all other 
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variables.  Follow-up data was not collected at standardized intervals following time 2 
assessment because of participants’ complicated lifestyles.  For example, because some 
participants were homeless, data collection was delayed at times.  Consequently, time 
was measured as number of days post-baseline.  All time 2 data was collected 14 days 
post-baseline.  Time 3 data was collected an average of 94.6 days (SD=35.3) post-
baseline.  Time 4 data was collected an average of 171.0 days (SD=13.8) post-baseline.  
Due to the imbalanced gender distribution between groups, we analyzed males only to 
determine if results were different, suggesting gender differences.  They were not and 
consequently, the following results reflect inclusion of all participants. 
3.3.1. Outcome measures 
ACT completers (i.e., 3 or more sessions; n=12) were compared to TAU 
participants (n=10).  The primary dependent variables for the outcome analyses were 
percentage of pills taken for the past 2 weeks, CD4 count, and viral load.  As noted 
above, data collection revealed pharmacy refill was not a useful measure of adherence as 
no participants indicated any significant delinquency in refilling their prescriptions.  In 
light of the baseline differences between groups on depressive symptoms, anxiety 
symptoms, and experiential acceptance, we considered using these variables as covariates 
in outcome analyses.  However, as noted above, none of these variables were 
significantly correlated with baseline dependent measures (i.e., percent adherence, CD4, 
viral load) nor were they correlated with percent adherence change over time.  Therefore, 
there were not used as covariates.  
Baseline percentage adherence was used as a covariate to provide a refined 
estimate of possible changes over time.  A main effect for time was found as participants 
 41 
as a whole showed a significant increase in percentage of adherence, as measured by the 
ACTG AI, from baseline through follow-up (γ10=7.65, t=1.20, d.f.=43, p=.008, d=.37).  
However, when examining each treatment group independently, results revealed 
percentage of adherence in TAU did not change significantly over time (γ10=4.12, t=2.03, 
d.f.=21, p=.056, d=.89) nor did it change significantly over time in the ACT condition 
(γ10=2.22, t=1.10, d.f.=29, p=.279, d=.41).  An interaction between time and condition for 
percentage of adherence was not found (γ11=2.12, t=1.46, d.f.=50, p=.152, d=.41) (see 
Figure 5 for summary of adherence changes over time).  Post-hoc power analyses 
revealed .63 power for this group of analyses. 
Baseline viral load was used as a covariate.  A main effect for time as a whole 
was not found as participants showed no significant decrease in viral load from baseline 
through follow-up (γ10=.002, t=.994, d.f.=46, p=.965, d=.29).  A main effect of TAU over 
time on viral load was not statistically significant (γ10=-1.01, t=1.00, d.f.=19, p=.328, d= 
.46) nor was a main effect found for ACT over time (γ10=3.28, t=1.81, d.f.=27, p=.081, 
d=.70).  An interaction between time and condition for viral load was not found 
(γ11=1.23, t=1.11, d.f.=46, p=.272, d=.33) (see Figure 6 for summary of viral load 
changes over time).  Post-hoc power analyses revealed .65 power for this group of 
analyses. 
Baseline CD4 was used as a covariate.  A main effect for time was not found as 
participants did not show significant changes in CD4 count from baseline through follow-
up (γ10<.001, t<.001, d.f.=38, p>.99, d<.001).  A main effect of TAU on CD4 over time 
was not statistically significant (γ10=2.93, t=-1.71, d.f.=16, p=.106, d=.86) nor was a main 
effect of ACT over time found (γ10=1.26, t=1.12, d.f.=27, p=.271, d=.43).  However, an 
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interaction between time and condition for CD4 was found (γ11=5.23, t=-2.29, d.f.=42, 
p=.027, d=.71).  The interaction was significant because participants in the ACT 
condition showed increased, albeit not statistically significant increases, in CD4 count 
whereas TAU participants showed decreased CD4 count over time.  In other words, the 
interaction indicates that ACT and TAU differed significantly over time in change in 
CD4 count.  But when examined alone, neither group showed a significant change from 
baseline to post-treatment (see Figure 7 for summary of CD4 changes over time).  Post-
hoc power analyses revealed .61power for this group of analyses. 
3.3.2. Overall group change 
Analyses were conducted to test for overall group change, regardless of condition 
and regardless of treatment completion status (i.e., null models).  Participants showed a 
significant increase in percentage of adherence from baseline through follow-up 
(γ10=7.91, t=1.41, d.f.=53, p=.007, d=.39).  Viral load did not significantly change over 
time (γ10=.02, t=-1.15, d.f.=50, p=.252, d=.33)  nor did CD4 (γ10<.001, t<.001, d.f.=40, 
p>.99, d<.001). 
Additionally, because of the inconsistencies of follow-up assessments, we 
examined trends in participants who completed all 4 assessments to determine any 
response biases.  As illustrated in Figures 8-10, participants who completed all 
assessments showed more variability in percent adherence over time, as compared to the 
larger group trends; similar patterns in CD4 changes over time; and no variation in viral 
load over time.  Therefore, it appears these participants were some of the most healthy 
individuals in the overall group, as evidenced by their low viral loads, but that their 
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medication adherence and CD4 were not static over time, suggesting some room for 
improvement. 
3.3.3. Process measures 
We examined changes in experiential acceptance and mindfulness for treatment 
completers.  Results suggested participants who attended at least 3 sessions showed some 
increase in experiential acceptance, trending towards statistical significance (γ11=3.53, 
t=1.88, d.f.=23, p=.073, d=.78).  Significant changes in mindful acceptance were not 
found (γ11=3.53, t=1.88, d.f.=23, p=.269, d=.78) nor were changes in mindful awareness 
(γ11<.001, t<.01, d.f.=28, p>.999, d<.01). 
3.4. Secondary analyses 
3.4.1. Correlation analyses 
Using Pearson’s zero-order correlations, results suggested baseline adherence was 
not correlated with measures of experiential acceptance, depression, anxiety, or 
mindfulness within the entire sample (p >.05).  Because time 4 data collection was 
limited, we focused on time 3 follow-up data (ACT=8 participants, TAU=8 participants) 
to examine the extent to which initial levels of affective symptoms and 
acceptance/mindfulness contributed as predictors of adherence at follow-up, compared to 
baseline adherence, using hierarchical regression analyses.  In a hierarchical regression 
predicting adherence at time 3 follow-up among all study participants, initial adherence 
was entered in the first step (see Table 5).  Next, initial depression, anxiety, acceptance, 
and mindfulness elements were entered in sequential steps.  Initial adherence (β=-.094, 
ΔR2 =.009, p=.729) was not a significant predictor of follow-up adherence nor was 
baseline depression (β=-.128, ΔR2 =.015, p=.660).  In contrast, baseline anxiety (β=-.887, 
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ΔR2 =.413, p=.012) was a significant predictor of adherence at follow-up. Among 
measures of acceptance and mindfulness, baseline acceptance (β=-.140, ΔR2 =.005, 
p=.756) and baseline mindful awareness (β=.589, ΔR2 =.037, p=.422) were not 
significant predictors of follow-up adherence, but baseline mindful acceptance (β=1.41, 
ΔR2 =.194, p=.046) was a significant predictor.  To summarize, results revealed higher 
levels of baseline anxiety predicted lower adherence at follow-up, while higher levels of 
baseline mindful acceptance predicted higher adherence at follow-up. 
CHAPTER 4. DISCUSSION 
4.1. Summary of Results 
 The current study was a pilot trial to develop and investigate the efficacy and 
effectiveness of an acceptance-based intervention to promote HIV medication adherence 
delivered in a group format, co-located in a primary care clinic for HIV+, uninsured 
individuals living in a large urban area.  The pilot intervention was compared to a control 
condition in which participants received education about HIV management and HAART.  
Results showed the intervention did not lead to statistically significant improvement in 
medication adherence or changes in important measures of the severity of HIV status 
compared to the control condition.  However, examination of effect sizes and interactions 
suggested the ACT intervention had a medium moderating effect on percent adherence 
and viral load count, as well as a large effect on CD4 changes.  Additionally, no 
significant relationship was found among baseline adherence and measures of 
acceptance, mindfulness, or symptoms of anxiety and depression. 
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 4.1.1. Qualitative Observations and Process 
 Despite the mixed statistical results, qualitative observations showed acceptance-
based intervention strategies were well-suited to this population.  One key point made in 
each session was that attempts to avoid the realities of living with HIV are futile, leading 
to worsened health.  Many participants corroborated this as they noted that their initial 
reaction to finding out they were HIV positive was to withdraw from social supports and 
medical care.  For some, they only sought treatment when their health significantly 
worsened and they could no longer live without medication.  Indeed, acceptance was not 
a new concept to participants as they recognized that taking an initial step towards HIV 
care required some level of acceptance that their HIV status would not change. 
 Considering none of the participants were treatment naïve, the crux of their HIV 
self-care was not necessarily admitting they needed HAART; instead, it depended on 
their commitment to taking the medication regardless of its side effects and seeking to 
live with HIV knowing the stigma and shame it could provoke.  Participants enjoyed 
commiserating about what medications worked, which ones were notoriously harsh on 
the body, and which ones tasted bad.  Relationships were the most important factor they 
discussed when troubleshooting life with HIV.  These discussions focused on familial 
relationships (e.g., sharing one’s HIV status with parents) and romantic relationships.  
New romantic relationships, in which one had not yet shared his/her HIV status, were 
particularly anxiety-provoking for some participants.  This connected well with the 
intervention’s emphasis on living value-driven lives.  Specifically, we discussed why 
people develop romance and want to connect with others.  We noted the importance of 
developing trust, confidence, and support from our romantic partners and how not 
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admitting one’s HIV status would limit how close we can be to others.  Therefore, the 
question was posed: do you want to avoid divulging your HIV status (due to fear of 
rejection, etc.), knowing that this may limit how close you will be to someone?  Or, are 
you willing to admit you are HIV positive because it will give you the chance to be closer 
to someone and allow you to care for your disease openly? 
 As noted above, the ACT intervention was designed to be experiential so that 
participants could reach insights through critical thinking, rather than via passive 
learning.  This made for many enjoyable session in which we discussed the power (or 
lack thereof) of simple words like “AIDS” and how our minds relish in the opportunity to 
struggle with thoughts and feelings.  This treatment had an effect on some participants 
because it was intuitive, yet new and exciting.  It allowed them to think critically of their 
HIV experience, to acknowledge their concerns without dismissal or minimization, and to 
develop pragmatic solutions to everyday struggles. 
4.2. Support for Hypotheses 
4.2.1. Hypothesis #1 
It was hypothesized that participants in the ACT condition would demonstrate 
greater improvements in adherence outcomes compared to those receiving TAU only.  
Support for this hypothesis was not found as no significant differences in adherence were 
observed between the conditions.  However, adherence change was observed across 
conditions.  This result is not surprising as data suggest education is an important means 
to improving adherence (Simoni et al., 2006b).  The lack of additional adherence 
improvement for participants in the ACT condition, beyond the changes observed in the 
control condition, may be explained by their relatively high level of experiential 
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acceptance at baseline.  Experiential acceptance was a proposed mediator for the ACT 
intervention and considering very little change in acceptance was observed during the 
course of intervention and follow-up, these participants may have already plateaued at 
functional levels of acceptance.  Alternatively, these results may question the impact of 
the ACT intervention.  Because the active ingredients of acceptance-based therapies were 
adapted for the population and setting, these results may suggest the intervention was too 
simplified or diffuse.  For instance, each session was designed to be free-standing leading 
us to distill acceptance-based technologies into concrete, efficient recommendations and 
strategies that may have undermined some of the cognitive changes one would expect in 
long-term, individual therapy.  Lastly, because this study was underpowered, effects of 
the ACT intervention on adherence may have been difficult to detect.  However, ACT did 
achieve some effect, as evidenced by effect sizes.  The large effect of ACT on biologic 
measures like CD4 suggests some elements of the active intervention lead to improved 
HIV-related health. 
Because of the small sample size, this study was underpowered.  Furthermore, 
follow-up data was not entirely complete.  We attempted to assess drop-outs’ biologics 
via chart review to determine if drop-out was systematic, but no conclusions could be 
drawn from our efforts.  Only two patients continued to follow-up with the clinic outside 
of the auspices of this study; the others did not return for medical care.  Therefore, we 
could not determine if some patients improved simply because a Hawthorne effect or 
because of a retention bias. 
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4.2.2. Hypothesis #2 
It was hypothesized that baseline experiential acceptance and mindfulness would 
be inversely correlated with medication adherence.  These hypotheses were not 
supported.  However, results revealed baseline mindful acceptance was a significant 
predictor of adherence at follow-up, when accounting for baseline adherence.  These 
mixed results are likely a by-product of the small sample size. To our knowledge, though, 
these are the first results to document a connection between mindfulness in the 
management of HIV and use of HAART.  These findings could indicate that future 
interventions targeting acceptance may be efficacious in the promotion of effective 
disease self-management.  Notably, none of the participants had participated in previous 
interventions to promote medication adherence, suggesting that those with high levels of 
acceptance arrived at this coping perspective naturally.  This is consistent with 
observations shared by some participants during and after groups.  For instance, some 
participants noted how “obvious” it was that acceptance was a precursor to effective 
disease management.  The ACT model focuses on promoting value-driven living, 
regardless of disease or symptom changes.  Consequently, individuals are expected to 
shift their attention from struggling with their illness to living with their illness.  Perhaps 
those HIV+ participants that did show higher levels of acceptance realized that struggling 
with HIV detracted from their lives. 
4.2.3. Hypothesis #3 
Lastly, we hypothesized baseline anxiety and depressive symptoms would be 
inversely correlated with medication adherence.  Despite notable symptoms of 
mood/anxiety disturbance, particularly in the TAU group, results did not support this 
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hypothesis.  Although all participants were sub-optimally adherent (<80%), they did 
adhere to their HAART prescriptions a majority of the time.  The variability in levels of 
adherence across participants could be influenced by affective symptoms though.  For 
instance, self-reported barriers like forgetfulness and fear of side effects are most likely 
connected to mood and anxiety symptoms. 
4.2.4. Supplementary findings 
Despite no statistically significant differences in changes in adherence over time 
between conditions, results revealed changes in CD4 were moderated by treatment 
condition.  Additionally, results revealed medium to large effect sizes for adherence 
change and change in biologics.  In fact, changes in viral load and CD4, which are most 
crucial in HIV care, were large.  Statistical testing did not show significance simply 
because of small sample size.  Indeed, both groups showed improved CD4 levels across 
time.  However, those in the ACT condition demonstrated improvement in a gradual 
manner, whereas those in TAU showed more fluctuation.   These results suggest changes 
in HIV self-care behavior may be more fickle over time when not accompanied by 
behavioral intervention.  In fact, these results are notable because they highlight the 
augmenting effects of behavioral interventions on psychosocial education.  Although 
education clearly is an important and powerful tool, it can be supplemented with 
strategies that may help patients maintain gains consistently over the long-term.  
4.3. Limitations 
 The current study possessed several strengths, including multi-modal assessment 
of adherence, a control condition, and a design that recognized the value of increased 
accessibility to behavioral intervention through the use of a co-located model of 
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treatment.  However, potential limitations must be considered when evaluating the 
results, particularly because the primary hypothesis was not supported.  The limitations 
include: small sample size, composition of the sample, and limited variety of 
interventionists. 
 Although clinic providers and staff were informed about the study and its aims 
and included in the project development, a majority of participants were self-referred or 
at least presented directly to the study rather than via direct referral between providers 
and study staff.  This may represent a number of flaws in the recruitment plan.  First, it 
may suggest providers and/or staff were not well enough informed about the study and 
did not either deem some patients eligible for the project or did not offer participation to 
those that could have been eligible.  Another explanation is that those patients most in 
need of this type of intervention did not regularly present to the clinic for care.  This 
would not be surprising as low adherence may be a byproduct of other life struggles, 
limiting a patient’s ability to attend healthcare appointments.  Data suggest those HIV+ 
patients most in need of education and intervention to aid their disease management are 
significantly less likely to attend medical appointments (Crum et al., 2006).  This may be 
further compounded by other barriers such as shame about not taking their medication as 
prescribed.  Thus, those participants willing to consent were likely somewhat higher 
functioning than other patients who could have benefited from this program.  The small 
sample size limited our ability to detect treatment effects, but effect sizes and 
examination of trends suggested acceptance-based intervention lead to some important 
changes in HIV-related outcomes.  As noted above, the predictive connection between 
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HAART adherence and mindful acceptance is a notable finding that warrants further 
investigation. 
The composition of the sample is a notable caveat when interpreting the results.  
Although the make-up of the sample (i.e., predominantly male and African-American) is 
consistent with demographic epidemiological studies of HIV prevalence (CDC, 2007), it 
does not include much representation of females or Latinos, two populations currently at 
higher risk for new HIV diagnosis.  Therefore, external validity is not necessarily limited 
but could be improved with a more diverse sample.  Furthermore, these participants were 
not significantly non-adherent as baseline mean adherence approached 80%.  This may 
have limited the impact of the ACT intervention.  However, these findings are not 
notably higher than most epidemiological data (e.g., Bartlett, 2002) and certainly 
represent suboptimal levels. 
Finally, all groups were conducted by the lead investigator.  Therefore, treatment 
effects or lack thereof may be related to the relative inexperience of the investigator, 
particularly in group interventions.  However, the investigator’s lack of treatment 
experience may have been a positive feature of this program as it would be expected that 
future co-located or integrated interventions would likely be conducted by a provider who 
may not be an expert in behavioral interventions or have a degree in psychology. 
4.4. Implications and Future Directions 
 HIV continues to be a significant health issue for millions of people worldwide.  
In the United States, living with HIV is possible because of the advent and availability of 
HAART.  However, the success of HAART is dependent on adherence: if patients do not 
take their medication as prescribed at least 90% of the time, the medications do not work 
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well and can in fact lead to negative health consequences.  Consequently, considerable 
behavioral health research has targeted medication adherence.  Some data suggest 
behavioral and cognitive approaches do lead to increased adherence.  However, a debate 
in the literature continues as it is unclear what type of CBT approach works best in this 
population and what type of delivery method is most viable. 
As such, the present study sought to examine the effects of an acceptance-based 
intervention to promote HIV medication adherence, co-located in a primary care clinic.  
Results did not show any significant changes in HAART adherence, although data did 
suggest mindful acceptance was an important predictor of adherence and that the 
acceptance-based intervention moderated follow-up CD4 levels, producing more 
consistent improvements in this important measure of HIV-related health.  The relative 
lack of findings may be due to small sample size, as effect size analysis showed medium 
intervention effects on percentage of adherence and viral load; a large effect size was 
noted for CD4 changes.  Due to the small sample size, future trials should be conducted 
in larger samples with more stringent controls on possible variables that may affect 
outcome.  Specifically, stratified block randomization should be used to control for 
baseline group differences in dependent measures and affective symptoms that may affect 
adherence.  Additionally, a more tightly designed study could balance for time between 
the intervention and control to determine if any intervention changes were due to 
attention or expectancy effects.  We chose a group format for the intervention to 
maximize efficient delivery of the intervention and because we expected participants to 
benefit from group-based discussions of disease management.  However, this design 
could have impeded recruitment or undermined some of the treatment effects.  An 
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important future consideration will be to apply acceptance-based strategies on an 
individual basis to determine if this improves efficacy. 
Furthermore, future iterations of this study should target patients with very low 
levels of adherence. Although all participants at baseline reported suboptimal adherence, 
they were not the most problematic cases encountered in the HIV clinic.  The effect of 
acceptance-based strategies would likely have a larger impact on those who are unwilling 
to even accept they should take medication s.  A better assessment of past medication 
usage would have further informed our understanding of when these strategies have the 
most impact on patients because past medication history influences expectancies and 
future self-care behaviors.  Finally, behavioral strategies that have been shown to be 
efficacious, such as pill diaries, should be used to ensure patients receive the best possible 
advice into what will help them improve adherence. 
The primary care setting has become the de facto mental health clinic in our 
country (Regier et al., 1993).  Therefore, it clearly is an important venue to which 
behavioral interventions must be applied to make these treatments more accessible and 
available to patients.  This is particularly needed in the treatment of HIV, which carries 
significant stigma and is often associated with poorer psychosocial functioning.  One way 
to make this study’s intervention more accessible would be to integrate behavioral 
interventions into routine primary care visits.  Data suggest patients who meet with 
physicians and behavioral specialists, such as social workers or psychologists in the same 
appointment, are more likely to receive the advice and skills they need and will be more 
likely to follow-up for behavioral health problems than patients referred to an outside 
mental health clinic (see Miller, Mendenhall, & Malik, 2008 for further discussion).  
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Therefore, some of the same techniques used in this project could be applied during 
routine visits in an effort to increase healthcare efficiency and to streamline the pathways 
to efficacious interventions.  Ultimately, acceptance-based interventions for HIV 
medication adherence will depend not only on more effective recruitment strategies, but 
will also depend on intervention accessibility. 
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Table 1. HAART Non-adherence Predictors (Ickovics & Meisler, 1997). 
 
 
Categories     Examples         
Individual 
factors    Perceived costs and benefits, social support 
Characteristics of the treatment 
regimen Pill burden, duration of treatment, side effects 
Patient and provider relationship Trusting, genuine     
Characteristics of the clinical setting Scheduling, confidentiality    
Presentation of HIV     Viral load, CD4 count, symptoms   
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Table 2. Assessment Schedule 
 
Baseline Session 3 6 wk. Follow-up 
12 wk. Follow-
up 
AAQ-2 AAQ-2 AAQ-2 AAQ-2 
BDI-II BDI-II BDI-II BDI-II 
BAI BAI BAI BAI 
PHLMS PHLMS PHLMS PHLMS 
        
CD4/VL CD4/VL CD4/VL CD4/VL 
ACTG AI ACTG AI ACTG AI ACTG AI 
Pharmacy Pharmacy Pharmacy Pharmacy 
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Table 3. Demographic and baseline variables by randomized condition 
 
Variables ACT (n = 16)  TAU (n = 10)  
 M S.D. M S.D. 
Age 
 
Self-report Measures 
   AAQ 
   BDI-II 
   BAI 
   PHLMS-Awareness 
   PHLMS- Acceptance 
 
HIV variablesa 
   Years since HIV Diagnosis 
   CD4 
   Viral Load 
   Prescribed doses per 2 weeks 
   HAART Adherence % 
 
52.5 
 
 
41.9 
10.0 
5.9 
41.0 
32.0 
 
 
12.1 
372.2 
148.8 
38.5 
79.2 
5.0 
 
 
11.7 
2.0 
4.2 
5.0 
9.7 
 
 
5.7 
167.4 
130.1 
20.1 
2.8 
50.8 
 
 
26.0 
21.4 
17.0 
43.4 
26.0 
 
 
13.0 
541.0 
55.0 
33.6 
77.1 
7.1 
 
 
10.1 
14.9 
16.6 
4.3 
12.2 
 
 
4.7 
301.5 
45.7 
11.8 
3.0 
 % N % n 
Gender 
   Female 
 
 
12.5 
 
 
2 
 
 
0 
 
 
0 
   Male 
 
Race/Ethnicity 
   African-American 
   Caucasian 
 
Marital Status 
   Single 
   Live w/partner/Married 
   Separated/Divorced 
 
Education 
   ≤ 11th Grade 
   High School 
   Some College 
   4 Year College 
 
Employment 
87.5 
 
 
87.5 
12.5 
 
 
37.5 
25.0 
37.5 
 
 
37.5 
25.0 
37.5 
0 
 
 
14 
 
 
14 
2 
 
 
6 
4 
6 
 
 
6 
4 
6 
0 
 
 
100.0 
 
 
80.0 
20.0 
 
 
100.0 
0 
0 
 
 
20.0 
60.0 
0 
20.0 
 
 
10 
 
 
8 
2 
 
 
10 
0 
0 
 
 
2 
6 
0 
2 
 
 
   Part-time 
   Disabled 
37.5 
62.5 
6 
10 
20.0 
80.0 
1 
8 
Note: ACT, Acceptance-based Therapy; TAU, Treatment-as-usual; M, mean; S.D., standard 
deviation.  a HIV variables are based on participant self-report.  Data were corroborated via 
medical chart review. 
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Table 4. Mean (Standard Deviations) at follow-up by randomized condition (sample size) 
 
Variables Time 2 Time 3 Time 4 
Self-report 
   AAQ 
   BDI-II 
   BAI 
   PHLMS-Aw. 
   PHLMS- Acc. 
 
HIV variablesa 
   CD4 
   Viral Load 
    Adherence % 
 
ACT (8) 
50.5 (4.0) 
5.3 (4.2) 
0.7 (0.5) 
41.0 (7.8) 
31.3 (12.5) 
 
 
440.0 (177.9) 
32.0 (24.8) 
94.6 (0.1) 
TAU (4) 
43.0 (0.5) 
6.0 (0.3) 
3.0 (0.1) 
33.0 (0.4) 
49.0 (2.3) 
 
 
706.0 (67.9) 
48.0 (15.6) 
92.9 (0.5) 
ACT (8) 
47.3 (4.1) 
9.0 (2.4) 
5.3 (3.4) 
35.3 (2.3) 
28.0 (3.9) 
 
 
487.3(225.3) 
16.0 (24.8) 
94.6 (0.1) 
TAU (8) 
27.8 (12.7) 
25.0 (19.4) 
35.3 (5.4) 
42.8 (6.6) 
20.0 (4.4) 
 
 
669.7(619.7) 
182.5(337.9) 
94.6 (0.1) 
ACT (6) 
46.3 (3.4) 
8.0 (5.0) 
3.3 (2.3) 
42.0 (3.9) 
28.0(12.1) 
 
 
524.3(285.4) 
70.0 (108.4) 
100 (0.0) 
TAU (4) 
17.0 (0.1) 
38.0 (0.3) 
19.0 (18.5) 
36.0 (12.7) 
33.5 (14.4) 
 
 
890.1 (208.4) 
25.0 (28.9) 
100 (0.0) 
       
Note: ACT, Acceptance-based Therapy; TAU, Treatment-as-usual; Mean (Standard Deviation).   
a HIV variables are based on participant self-report.  Data were corroborated via medical chart 
review. 
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Table 5. Hierarchical regression analysis predicting adherence at follow-up (n=16) 
 
Step 1     β SE p F df ΔR2 
Baseline adherence 
 
-0.094 0.098 0.729 0.125 (1,14) 0.009 
         Step 2 
  
β SE p ΔF df ΔR2 
Baseline depression 
 
-0.128 0.002 0.66 0.202 (1,13) 0.015 
         Step 3 
        Baseline anxiety 
 
-0.887 0.002 0.012 8.795 (1,12) 0.413 
         Step 4 
        Baseline experiential 
avoidance -0.14 0.003 0.756 0.102 (1,11) 0.005 
         Step 5 
        Baseline mindful awareness 0.589 0.013 0.422 0.7 (1,10) 0.037 
         Step 6 
        Baseline mindful acceptance 1.409 0.007 0.046 5.349 (1,19) 0.194 
 
Note: Total Adjusted R2=.673; Baseline depression, Beck Depression Inventory-II; Baseline 
anxiety, Beck Anxiety Inventory; Baseline experiential avoidance, Acceptance and Action 
Questionnaire-2; Baseline mindful awareness, Philadelphia Mindfulness Scale-Awareness 
subscale; Baseline mindful acceptance, Philadelphia Mindfulness Scale-Acceptance subscale. 
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Figure 1. Model of the role of experiential control/avoidance in HIV 
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Figure 2. Participant recruitment and assessment flow 
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Figure 3. Baseline participant Viral Load 
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Figure 4. Baseline participant CD4 
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Figure 5. Group comparisons of percent HAART Adherence 
*ACT: T1 n=12; T2 n=8; T3 n=8; T4 n=6 
**Control: T1 n=10; T2 n=2; T3 n=8; T4 n=4 
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Figure 6. Group comparisons of Viral Load 
*ACT: T1 n=12; T2 n=8; T3 n=8; T4 n=6 
**Control: T1 n=10; T2 n=2; T3 n=8; T4 n=4 
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Figure 7. Group comparisons of CD4 count 
*ACT: T1 n=12; T2 n=8; T3 n=8; T4 n=6 
**Control: T1 n=10; T2 n=2; T3 n=8; T4 n=4 
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Figure 8. Group comparisons of Percent Adherence for participants that completed all 4 
assessments (ACT: n=6; Control: n=4) 
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Figure 9. Group comparisons of CD4 for participants that completed all 4 assessments 
(ACT: n=6; Control: n=4) 
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Figure 10. Group comparisons of Viral Load for participants that completed all 4 
assessments (ACT: n=6; Control: n=4) 
 
  
 77 
 
 
 
Appendix A: Acceptance-based Intervention Manual 
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Acceptance-based Intervention to Promote 
HIV Medication Adherence in the Primary 
Care Setting 
 
 
 
Therapist Manual 
 
Ethan Moitra, M.S. 
James D. Herbert, Ph.D. 
Evan M. Forman, Ph.D. 
 
 
 
 
 
 
Department of Psychology 
245 N. 15th Street, MS 988 
Philadelphia, PA 19102-1192 
Phone: 215-762-3327 
Fax: 215-762-8706 
Email: em742@drexel.edu  
Website: http://www.drexel.edu/coas/psychology/formanherbert/ 
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Note: This manual is based on the six sources below.  Detailed descriptions of the 
inspiration for this manual are available within these documents. 
 
Dalrymple, K.L., & Herbert, J.D. (2005). Acceptance and Commitment Therapy for 
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Background 
Human immunodeficiency virus (HIV) is a global health concern.  Although effective 
pharmacological treatments, such as highly active antiretroviral therapy (HAART) have 
been developed and implemented, a significant number of adults with HIV in the U.S. do 
not maintain adherence at adequate levels for treatment to work.  The data suggest HIV 
medications should be taken 90% of the time or more, though typically Americans with 
HIV take their medications 60% to 70% of the time (Bartlett, 2002). 
 
Non-adherence to antiretrovirals has somewhat more dire consequences than non-
adherence to other types of medication.  Resistance develops relatively quickly in 
patients who have even brief gaps in adherence.  Furthermore, because some medications 
(particularly those in the same class) share similar mechanisms of action, cross-resistance 
can occur, which means not only that one type of medication is no longer effective for a 
given patient but that all medications in the same class no longer work, eliminating the 
future use of many drugs. Another concern is the ability of persons with treatment-
resistant HIV to pass a resistant form of the virus to another person, thereby limiting the 
second party’s treatment options early in the course of the infection (Kelly, Otto-Salaj, 
Sikkema, Pinkerton, & Bloom, 1998).   
 
Many individuals with HIV are simply given their prescription and instructed to follow 
their physician’s recommendations regarding dosing, timing, etc.  Although this approach 
may be sufficient for some patients, a majority requires more than basic education.  In 
fact, a variety of factors influence adherence to HAART regimens among patients with 
HIV, including various individual and environmental factors.   
 
Some studies have shown the use of traditional cognitive-behavior therapeutic (CBT) 
strategies to be efficacious in promoting HIV medication adherence.  For instance, 
successful studies have used classic CBT tools such as teaching patients to dispute 
irrational thoughts (e.g., about their mortality) to foster motivation to become more 
adherent.  Generally, these programs have used a combination of cognitive 
restructuring/disputation strategies combined with behavioral techniques.  Results have 
shown medium to large effect sizes.  However, these programs are often circumscribed to 
tightly controlled research environments and lack external validity.  This is particularly 
worrisome as many HIV clinics have limited resources and patients, themselves, have 
limited time and money.  Furthermore, the fundamental basis of CBT is that irrational 
thoughts and beliefs should be changed, which can be quite challenging for individuals 
with HIV.  Specifically, denial has been shown to significantly affect adherence and other 
healthy behaviors.  Despite being able to rationally agree that their self-management 
behaviors should improve, a patient’s lack of psychological acceptance of the disease and 
its implications presents a barrier that may be difficult to overcome via traditional CBT. 
 
Therefore, an acceptance-based intervention approach to HAART adherence may be 
preferable in this population, in part because of the significant role played by denial.  A 
lack of acceptance of the diagnosis and its implications, in addition to ongoing fear of 
stigma and associated community reactions, limit the openness of many HIV patients 
about their disease and its management.  Due to fear of stigmatization and judgment, 
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many individuals avoid discussing their diagnosis and suppress thoughts associated with 
living with HIV.   
 
This manual will outline a treatment approach that integrates education with strategies to 
promote acceptance of thoughts, feelings, and physical sensations associated with living 
with HIV.  Through acceptance strategies, patients will learn to manage their HIV while 
regaining focus on living a personally fulfilling, value-driven life.  Additionally, this 
manual will describe how to deliver this intervention in a front-line, community-based, 
outpatient, primary care setting, where resources are likely limited. 
 
Individuals with HIV wish that they did not have the disease.  The diagnosis of HIV can 
be frightening and overwhelming.  However, despite HIV’s chronicity, it is no longer a 
terminal illness; the use of HAART allows people to live with HIV.  Living with HIV, 
though, requires many lifestyle changes.  Some examples include: 
1. Strict adherence to a medication regimen to prevent the virus from proliferating 
2. Safe-sex practices to prevent HIV transmission 
3. Living with and tolerating others’ reactions to disclosure of HIV+ status 
 
These changes can be difficult to make, particularly because they require vigilance and 
ongoing consideration for the remainder of a person’s life.  Adapting to the needs of 
living with HIV is challenging.  Undoubtedly, the stresses associated with not adhering to 
these requirements further complicate the situation for HIV+ individuals.  Consequently, 
the phenomenon of denial is unsurprising.  Many HIV+ individuals report they would 
rather think about anything else than think about having HIV, what it means for their 
long-term health, and what changes it requires them to make to be able to live a healthful 
life.  In order to avoid and deny the fears and responsibilities associated with HIV, it 
becomes increasingly challenging to adhere to a medication regimen as it serves as a 
constant reminder of the disease. 
 
Structure of the Treatment 
The goal of this treatment is to promote medication adherence and to help patients live a 
value-driven life.  Therapists are advised to guide patients towards these goals by 
compassionately supporting patients’ anxieties, fears, and worries related to their disease.  
The framework for this treatment stems from Acceptance and Commitment Therapy 
(ACT), developed by Hayes, Strosahl, and Wilson (1999).  ACT encourages patients to 
“defuse” from distressing psychological experiences and to adopt an accepting stance 
towards one’s experience as it unfolds in real time.  This contrasts with traditional 
cognitive therapy, which is predicated on the assumption that therapeutic effects are 
mediated by changes in cognitions, including thoughts, beliefs, and schemas, and 
correspondingly emphasizes cognitive change efforts.  ACT also stresses exercises aimed 
at identifying and crystallizing key personal values, translating these values into specific 
behavioral goals, and designing and implementing behavior change strategies to realize 
those goals.  ACT promotes the concept of “committed action” as movement towards 
one’s goals in the context of experiential acceptance, thereby encouraging individuals to 
clarify and prioritize values in their lives.  In this population, a lack of clear values and 
goals might be instrumental in reducing medication adherence. 
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ACT relies heavily on metaphors and experiential exercises.  There are dozens of such 
exercises and metaphors that have been developed, and the list is constantly growing.   In 
fact, ACT is conceptualized as an evolving approach, and therapists are free to generate 
their own exercises and metaphors.  In order to achieve a degree of consistency in the 
implementation of the present protocol, there are certain key metaphors and exercises that 
should generally be used with all patients; these are contained in shaded boxes.  Patients 
may have different reactions to the various metaphors or exercises; therefore, it is 
generally helpful to continue to refer to those metaphors and exercises that particularly 
resonate with a particular patient. 
 
In order to remain consistent with the ACT model, it is as important to attend to errors of 
commission as well as errors of omission.  That is, the therapist must take care to avoid 
certain strategies that run counter to the ACT model.  This concern is likely to be 
especially relevant for experienced therapists who have trained in other models.  For 
example, cognitive therapists are accustomed to using strategies such as cognitive 
restructuring, in which the content of negative thoughts is challenged on logical and 
empirical grounds, and have developed a variety of technologies to accomplish this goal.  
In the ACT model, however, such a strategy would be inappropriate, since the content of 
thoughts is not viewed as the problem.  Similarly, psychodynamic therapists tend to focus 
on historical relationships and conflicts, whereas the focus in ACT is primarily on the 
present, with an eye toward the future.  As a final example, behavior therapists often 
assume that the treatment goals are obvious (e.g., anxiety reduction in the case of anxiety 
disorders, decrease in alcohol use or even abstinence in the case of alcoholism).  The 
ACT model, however, stresses exploration of personal values, and goal setting consistent 
with those values, and makes few a priori assumptions about what the specific goals of 
treatment for any individual should be. 
 
The treatment consists of weekly 60-minute sessions conducted in a group format.  Each 
session will serve as a free-standing intervention in which the overall acceptance-based 
principles will be discussed and implemented.  These core principles include developing 
openness to an acceptance perspective, fostering a willingness to accept HIV-related 
distress, and directing patients towards clarifying and focusing on life values.  Treatment 
will include educational information, experiential group exercises, role plays, and 
homework.  As noted above, each session is free standing and patients can begin 
treatment at any session because the sessions will be offered in successive weeks.  
However, an ideal course will consist of attending five sessions and will be considered 
minimally complete via attendance of three sessions.   
 
Each session follows a similar pattern of steps.  Initially, patients are given broad 
information about HIV and its complications and specific information about HIV 
medications and their importance.  Next, psychological and motivational barriers to 
effective self-management are examined.  This includes avoidance-based coping 
strategies and discussion of the interference caused by negatively-evaluated thoughts and 
feelings.  Acceptance is offered as a novel strategy and discussed in the context of 
willingness and mindfulness techniques.  Lastly, didactic and acceptance elements are 
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integrated and patients are encouraged to reorient themselves to values via between-
session homework.  The specific content of sessions will vary, although they will share 
the same basic format and themes. 
 
Group Structure 
The present treatment group is designed for use with primary care patients, who may not 
be seeking psychological intervention.  Groups can be promoted as “classes” or 
“workshops” if desired, rather than using the traditional psychotherapy term, “session.” 
 
Treatment can be delivered in a variety of settings, depending upon available resources 
and organizational needs.  If treating primary care patients, it is recommended that 
treatment occur within the primary care setting.  A medium-large conference room or 
classroom where patients can form a circle is optimal. 
 
Group Leader Characteristics 
This manual is written with two broad assumptions in mind:  (a) that the reader is 
generally familiar with the “nuts and bolts” of group psychotherapy (e.g., rapport 
building, attending and listening skills, ethical issues), and (b) that the reader is already 
familiar with the complications and treatments of HIV.  Discussion of common 
psychotherapeutic factors is therefore not included, nor is a detailed discussion of HIV. 
 
In this context, this manual should be viewed as an adaptation of the primary ACT 
textbook, Acceptance and Commitment Therapy, by Hayes, Strosahl, and Wilson (1999).  
It is imperative that the book be read carefully before attempting to implement this 
manual as it provides an in-depth discussion of the theoretical background, intervention 
strategies, and specific techniques that characterize the approach.  In addition, ongoing 
supervision by an experienced ACT therapist is critical. 
 
This Manual 
This manual is designed to provide content and process information to facilitate delivery 
of the treatment.  It is written directly for the therapist as reader.  Most comments are 
descriptive.  However, verbatim quotes to guide the presentation of exercises and 
metaphors are contained in shaded boxes.  The therapist is encouraged to loosely adhere 
to these quotes, adapting them as needed.  Finally, introductory remarks and concluding 
remarks will be repeated in each session.  For the sake of brevity, these remarks are not 
fully described in each session’s outline.  Instead, refer to the Session 1 outline for a 
detailed description of these elements.
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Outline of Treatment Sessions 
Each session is structured according to the following format: 
1. Introduction and outline of group expectations 
2. Review homework 
3. HIV-related education 
4. A combination of ACT exercises (*note some exercises may incorporate 
overlapping ACT elements) 
a. Creative hopelessness exercise 
i. Creative Hopelessness is a core element in ACT in which people 
are guided to recognize their control strategies have not helped 
their psychological and physical health, and in many cases have 
made them worse.  In this population, it is theorized that 
inconsistent medication adherence is related to an avoidance of 
thoughts and discussions of HIV+ status, an unwillingness to 
accept the HIV diagnosis, and unhealthy behaviors including drug 
use. 
b. Cognitive Defusion exercise 
i. Cognitive Defusion can be defined as the ability to distance oneself 
from internal stimuli.  Essentially, this means viewing “thoughts as 
thoughts,” products of the mind that are not necessarily true, and 
therefore, should not dictate behavior.  HIV+ patients are likely to 
be “fused” to fears regarding their disease, the stigma that it 
entails, and future concerns. 
c. Acceptance exercise 
i. Acceptance means embracing the full range of one’s ongoing 
experience, including distressing thoughts, feelings, sensations, 
memories, etc., fully and without defense or avoidance.  
Psychological acceptance relies heavily on the development of 
willingness.  The goal of willingness is not to feel better; instead, 
patients focus on experiencing all feelings, whether good or bad.  
Patients with low medication adherence rates can be expected to be 
low in acceptance/willingness because they likely avoid the 
psychological distress associated with living with HIV.  A willing, 
accepting perspective directly confronts denial.  This avoidance 
may be experiential (i.e., they refuse to  acknowledge their disease 
and its responsibilities) and/or behavioral (i.e., they refuse to attend 
medical appointments, take their medications, etc. because it 
would mean admitting illness). 
d. Mindfulness exercise 
i. Mindfulness techniques are used in this treatment to improve 
patients’ abilities to be aware and accepting of present-moment 
experiences.  Bringing attention to the many moments in life, fully 
and nonjudgmentally, facilitates acceptance.  Mindfulness connects 
to medication adherence because healthy self-management 
behaviors depend on nonjudgmental awareness of internal and 
external experiences. 
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e. Committed Action exercise 
i. Committed Action incorporates the techniques listed above into a 
concrete behavioral plan.  Each plan will be individualized 
according to the patients’ specific needs. 
5. Wrap-up and homework 
a. Most weeks’ homework assignments will include a Values exercise. 
i. Values provide an impetus for assuming an accepting perspective 
towards life.  Specifically, if a patient is accepting of his/her 
disease management responsibilities, he/she is more likely able to 
focus on developing a meaningful life, rather than simply avoiding 
taking medication.  Values are chosen life directions that guide our 
behaviors.  Due to their illness, many HIV+ patients can be 
expected to be “stuck” in their lives, having lost sight of their 
values and what they want to experience in life.  By accepting their 
disease and its responsibilities, patients can be expected to gain 
freedom to focus on other aspects of their lives in such areas as 
family, career, education, spirituality, etc. 
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Session 1 
 
 Introductions and review of group requirements/expectations: 
o It is important to begin each session with group member introductions.  
Ask patients to state their name, how long they have been diagnosed with 
HIV, and what they hope to gain from participating in this group. 
 This exercise encourages group participation and sets the tone for 
future discussions, emphasizes tailoring treatment to individual 
goals/needs, and allows patients to recognize similarities between 
themselves and other group members. 
o Respect the need for confidentiality. 
 Treatment is delivered in a group format.  Much of what will be 
shared is of a personal and sensitive nature. Note information 
shared in the group should not be shared with anyone outside of 
the program. 
o Respect each other’s point of view. 
 Explain each patient has something important to add so everyone’s 
comments and viewpoints should be respected. 
o Need for promptness. 
 Advise patients to arrive 10 to 15 minutes before the start of the 
group to complete questionnaires. 
o Starting on time. 
 Explain groups will start on time due to the large amount of 
information contained in this program and the limited amount of 
time for groups to meet.  Note late patients will miss important 
information and will be asked to stay a few minutes after group to 
complete questionnaires. 
o Homework completion 
 Explain each group will conclude with some assignments to 
complete between sessions.  Emphasize the value of these 
assignments and how they will help solidify concepts discussed 
each week. 
 HIV-related education 
o Many patients will be quite familiar with these educational points.  
Therefore, this didactic segment leads nicely into a discussion of what 
hasn’t worked.  The leader may ask, “Well, if you know these things so 
well, why aren’t you taking your medication?” 
 Discussion of problems with adhering to medications, including a dialogue 
using the following questions: 
o What have you tried? 
 Has it worked? What hasn’t? 
 What worked at first, but eventually did not?  Why did success 
decrease over time? 
• Responses likely will include some concrete strategies 
aimed at remembering.  These strategies are likely 
‘workable’ if done correctly, which often requires 
 87 
persistence.  These potentially workable attempts warrant 
reinforcement.   
• However, the scope of this discussion should be steered to 
the psychologically/emotionally-relevant challenges of 
accepting the medications and their effects on the patient’s 
daily life.  The therapist should focus on domains in which 
experiential avoidance is interfering with the goal of 
adherence.  Medications cause side effects, limit a person’s 
routine, and generally impose time/energy constraints on 
patients with HIV.  Any of these may present a barrier.  
Additionally, impediments to workable behavioral 
strategies (e.g., keeping pill boxes) may include fears of 
others asking questions about why the patient has pills.  
Another barrier may be that the patient simply refuses to 
fill pharmacy prescriptions.  Both examples hinge on the 
fear of stigmatization and HIV-acceptance.  Clearly, 
avoiding filling prescriptions eliminates the risk of 
disclosing HIV+ status.  However, in the long term, this 
behavior does not dispel this fear and has significant health 
consequences. 
 Person in Hole metaphor (creative hopelessness) 
o This metaphor is expected to resonate with patients because it emphasizes 
the hopelessness of their situation.  The HIV+ diagnosis will not change.  
The medications will have side effects.  Therefore, instead of focusing on 
strategies that have not worked (e.g., avoiding disclosure, avoiding taking 
medications, etc.) to ameliorate or minimize symptoms, they are 
encouraged to develop new strategies.  Describe the following situation: 
 
 
 
 
 
 
 
 
 
 
 
 
 
o It is important at this stage to avoid prematurely suggesting an alternative 
to the control agenda.  It is important that the patients actually experience 
the unworkability of their system in order to be as open as possible to a 
radically new way of conceptualizing the problems.  It is common for the 
patients to ask, “So what do I do then?” at this stage, and there is a 
temptation on the part of the therapist to say something like, “Well, the 
“Imagine you’re placed in a field, wearing a blindfold, and you’re given a little 
tool bag to carry.  You’re told that your job is to run around this field, blindfolded.  That 
is how you are supposed to live life.  Now, unbeknownst to you, in this field there are a 
number of widely spaced, fairly deep holes.  So you start running around and sooner or 
later you fall into a large hole.  You feel around, and sure enough, you can’t climb out 
and there are no escape routes you can find.  Probably what you would do in such a 
predicament is take the tool bag you were given and see what is in there.  Suppose the 
only tool in your bag is a shovel, so you start digging.  But still you are in a hole.  You 
try to dig harder and put in all this effort and all this work, and oddly enough, the hole is 
getting bigger and bigger.  So maybe the whole agenda is hopeless – you can’t dig your 
way out, that just digs you in struggling with its content, notice what hooked you.”   
(Hayes et al., 1999) 
 88 
key is to accept your diagnosis and focus on behavior change.”  There are 
several problems with this statement, however, not the least of which is 
that such a statement greatly oversimplifies any actual solution, and will 
likely be viewed as dismissive of the patient’s suffering.  Instead, the 
therapist can respond to such questions by saying something like, “I think 
that there is a way out of the puzzle, and that by working together we can 
figure out what that will be for you.  The important thing at this stage 
though is just to appreciate how all of the ways you’ve tried to control 
your stresses in order to move forward with your life have not worked.” 
 The take-home message is that it is not a lack of effort that’s the 
problem remains, but rather the fundamental system that does not 
work, because it cannot work. 
 
 Ask patients about their struggles with HIV.  Encourage them to discuss how they 
may feel stuck and frustrated by the fact that their HIV will not go away and that 
it requires many lifestyle changes.  Allow patients to relate their attempts to 
ignore their diagnosis to digging a deeper hole. 
 Briefly discuss the barriers to giving up an unworkable agenda.  In addition to the 
powerful effects of inertia and habit, the patient’s mind is constantly analyzing the 
situation in an effort to figure out what to do next.  Introduce the possibility that 
perhaps one can learn to react in an adaptive way without such analysis.  Note 
Yogi Berra’s famous quote regarding baseball:  “don’t think, just hit.”  Sometimes 
(like in baseball), analysis actually gets in the way of achieving one’s goals.  In 
other words, as we explore alternative ways of coping, the patient’s mind is likely 
to raise many objections. 
 
 Tug-of-War with a Monster (defusion & acceptance) 
o As an alternative to struggling, describe the following: 
 
 
 
 
 
 
 
 
o Using a rope, string, or other object, act out this Tug-of-War with a 
volunteer.  Ask the volunteer to play the role of “HIV Monster” and for 
you, the therapist, to play the role of patient.  Instruct the HIV Monster to 
yell and complain, using thoughts he/she typically has about HIV and the 
problems it causes in one’s life.  Struggle briefly then drop the rope, while 
the Monster continues to challenge you.  Then, ask the rest of the group to 
comment on how the dilemma has changed. 
o This metaphor helps HIV+ patients recognize letting go of a futile struggle 
is a viable option.  They realize struggling with the realities of living with 
HIV can be exhausting, frustrating, and distracting, among other reactions.  
“The situation you are in is like being in a tug-of-war with a monster.  The monster 
is life with an HIV diagnosis.  It is big, ugly, and very strong.  In between you and the 
monster is a pit, and so far as you can tell, it is bottomless.  If you lose this tug-of-war, you 
will fall into this pit and will be destroyed.  So you pull and pull, but the harder you pull, 
the harder the monster pulls, and you edge closer and closer to the pit.  The hardest thing to 
see is that our job here is not to win the tug-of-war…Our job is to drop the rope.”  (Hayes 
et al., 1999) 
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Acceptance means to experience whatever you are thinking or feeling; it’s 
“dropping the rope.” 
o In addition to noting how one cannot win the tug of war, the following 
points should be addressed in the context of this metaphor:  (a) one 
nevertheless must pay a price for “dropping the rope” and abandoning the 
struggle with HIV, namely, that one must accept that the monster (HIV) 
still lives on the other side of the moat, and will still taunt the patient from 
time to time; (b) as long as one really drops the rope, the monster cannot 
cause any harm, and the individual is in fact completely free of the 
monster’s influence and can maneuver about and do whatever one needs 
to do; and (c) that dropping the rope is a process, not a single act.  Even if 
the patient successfully drops the rope, he/she will invariably pick it up 
again instinctually when the monster rears its ugly head.  The key is to 
notice when one has picked up the rope, and gently put it down again.  
This “letting go of the rope” may happen 100 times per day, which is fine; 
the key is simply to drop to rope when you realize you’re holding it. 
o This exercise also provides an introductory opportunity for a discussion of 
mindfulness and the challenges of being mindful.  Furthermore, it hints at 
defusion and taking an accepting stance towards internal experiences. 
o Connect this to HIV and medication adherence by highlighting the 
purpose of increased mindfulness, i.e., to foster an ability to become aware 
of private experiences without intervening to attempt to change them, 
which then permits taking behavioral action toward one’s goals.   
 
 Wrap-up and homework 
o Session review: The take-home message from the Person in Hole 
metaphor is that it is not a lack of effort that is the problem (as evidenced 
by his/her many attempts to control stresses associated with HIV), but 
rather the fundamental system that does not work, because it cannot work.  
Note willingness to experience events associated with HIV (disclosure, 
taking medications, etc.) may afford the patient the opportunity to be less 
caught up in the struggle with living with HIV and therefore, free to 
pursue important life goals.  Lastly, note practiced mindfulness will help 
us further recognize and nonjudgmentally observe thoughts and feelings 
associated with HIV. 
o Highlight importance of continuing to think about topics discussed in 
today’s session over the next week.  Also note that homework will be 
assigned at the conclusion of each session to promote continued work 
between sessions.  Emphasize the importance of completing homework. 
o Distribute Mindfulness Meditation hand-out and Monitoring Form 
 Encourage patients to practice mindfulness mediation for a 
minimum of two 1-minute sittings, plus “real-time” mindful 
awareness.  On the Monitoring Form, the patients should record 
the data and time the mediation was practiced, a brief narrative of 
their experience/observations, and the percent of time they just 
noticed, rather than struggled, with the thoughts/feelings. 
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Session 2 
 
 Introductions and review of group requirements (see Session 1 for details) 
 Review of key elements of Session 1: Briefly review the ineffectiveness of prior 
attempts to eliminate stresses associated with living with HIV, highlighting the 
idea that simply trying to work harder on the same strategies is doomed to failure 
if the fundamental agenda is flawed.  Note willingness provides an alternative to 
the control agenda. 
o A continued dialogue regarding barriers to medication adherence should 
be initiated.  Some patients may not have attempted to increase adherence.  
This provides the opportunity to examine reasons why they did not 
comply and how this resistance may be related to their struggles with 
medication adherence.  It is important for the therapist to not dismiss non-
adherence (and thereby reinforcing avoidance), while at the same time 
striking an empathic and supportive tone. 
 HIV-related education 
 Quicksand metaphor (creative hopelessness) 
o Highlight the variety of ways patients may have struggled with medication 
adherence and its related stresses.  Encourage patients to assess their 
success in combating these barriers.  Note the “solutions” they have 
sought and how their struggle has caused further frustrations and 
suffering. 
o This metaphor serves to highlight the counterintuitive nature of the 
acceptance-based perspective.  Explain: 
 
 
 
 
 
 
 
 
 
o Following presentation of this metaphor, engage patients in a discussion 
regarding how this metaphor relates to their experience with HIV 
medications.  Highlight the importance, despite its counterintuitive nature, 
of letting go of the struggle to successfully overcome the problem. 
 
 AIDS, AIDS, AIDS (cognitive defusion) 
o This defusion technique is not intended to eliminate or manage pain.  
Instead, its aim is to help patients become more flexible in their day-to-
day living by becoming more aware of the process of thinking.  A 
significant impediment to being willing to accept the HIV diagnosis and 
the negative reactions it may provoke is that the terms “HIV” and “AIDS” 
are heavily-laden with negative connotations.  However, these 
connotations are somewhat dated as science has shown us all people are 
“Imagine you are in the middle of a pool of quicksand.  No ropes or tree 
branches are around to help you.  When people step into something they want to get 
out of 99.9% of the time, the most effective action to take is to walk, run, step, or 
jump out of trouble.  However, this is not the case with quicksand.  The more you 
struggle to push the sand away to get it off of you, the more you get pulled down (it’s 
like a vacuum that sucks you down).  If you fall in the quicksand, the only way to 
keep yourself from drowning is to do the opposite of what your natural inclination is 
to do; that is, you need to lie flat and still so that you have a larger surface area.”  
(Gregg et al., 2005) 
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vulnerable to the disease (it can infect anyone, not just drug users and gay 
men) and that treatment advancements have shown adults in the U.S. can 
live long, fulfilling lives with the disease.  Summarize these points for the 
patients.  Begin with the following statement and questions: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Conclude this exercise by asking patients to explain how this relates to 
their struggle with HIV.  Ideally, they should begin to recognize that their 
preconceived notions about the disease and how others will react to it are 
products of their minds.  Generally, it suggests thoughts and feelings are 
not necessarily true and that one can simply acknowledge the thought or 
feeling without trying to evaluate its truth.  This then frees us up to move 
forward toward chosen values. 
 
 Being willingly out of breath (acceptance) 
o This exercise provides a simple, experiential example of practicing 
willingness.  Begin by reintroducing the concept of willingness, reminding 
patients about the Tug-of-War with a Monster metaphor.  Ask patients to 
describe their interpretation of willingness.  Note willingness can 
specifically address thoughts they are having related to denial of the HIV 
diagnosis and other fears they believe impede their medication adherence.  
Note grasping willingness from an intellectual perspective is important but 
actually learning to put it into practice is paramount. 
o Thus, this exercise will help illustrate what the experience of intentionally 
being willing feels like.  (Pay careful attention to the clock during this 
“I want you to think about AIDS.  What comes to mind when you think about AIDS?  
Do any images come to mind?  How about any feelings?” 
 
Encourage a brief discussion among the group, soliciting patients’ varied responses. 
 
“Now we are going to try a very simple exercise to experience how a negative word 
can be experienced without being harmful.  When I say, ‘GO!’ start saying the word ‘AIDS’ 
out loud and as fast as you can.  Just keep saying the word ‘AIDS’ over and over the whole 
time.  Say it as quickly as possible while still fully pronouncing the word.  Pay attention to 
what happens because we will talk about the experience after you finish.” 
 
Ensure a clock or stopwatch is available.  Say, “GO!” and allow the patients to repeat 
“AIDS” for approximately 30 seconds.  At the end of 30 seconds, say “STOP!” 
 
“How did that feel?  What was your experience saying ‘AIDS’ over and over? 
(encourage some discussion)  After saying ‘AIDS’ as quickly as you could, what happened to 
the meaning of the word?  Did the word still invoke the same images and feelings it had when 
we first started discussing it?  Lastly, did you notice anything new that might have happened?  
For example, many people find the sounds of the word start to sound odd and maybe blend 
together.  Also, many people find the word starts to lose its believability and its emotional 
function.”  (Hayes et al.., 1999) 
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exercise, making sure not to allow the group members to hold their breath 
for too long.)  Read the following instructions: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o It is imperative to connect this exercise to HIV-related experiences.  
Encourage patients to discuss how increasing willingness might affect 
their behavior (e.g., if they were more willing to accept their HIV 
diagnosis, would they be more willing to fill their prescriptions?).  A 
common fear may be stigmatization.  Ask patients to provide examples of 
being judged for being HIV+.  Encourage patients to describe how this 
experience affected future interactions with strangers, etc.  Ask patients to 
imagine what disclosure of HIV status to a stranger will “feel” like.  Have 
they ever “taken the risk” of disclosure to gain a friend, confidant, or 
romantic partner?  Would they be willing to disclose in the future if it 
meant they could more readily pursue their life values? 
o These final points connect nicely to the next exercise, which aims to 
promote cognitive defusion via a simple verbal exercise.  Willingness (as 
well as mindfulness) facilitate cognitive defusion by affording the patient 
the opportunity to see internal events objectively and therefore not feel 
compelled to respond to them with control strategies. 
 
 Epitaph exercise (values) 
o Ask the patient to share one or two items from their Epitaph.  This is a 
values exercise that should be connected to willingness and the control 
agenda.  Note how the patient did not report wanting to be remembered for 
maladaptive behaviors such as, “Being really good at hiding her HIV 
diagnosis.”  Note values “dignify” willingness in that they provide a 
rationale for “dropping the rope.”  Increased willingness to live with HIV 
affords the opportunity to focus on other aspects of one’s life that will 
provide meaning, personal fulfillment, etc. 
 
“You are going to see how long you can hold your breath.  At the count of 3, start to 
hold your breath.  1…2…3…Notice exactly where the urge to breathe begins and ends in your 
body.  Locate exactly where you feel the urge to breathe.  See if you can allow that feeling to 
be there and at the same time, keep on holding your breath.  Turn your willingness dial all the 
way up!  Just feel the feeling and do not breathe.  Notice any thoughts that come up, and gently 
thank your mind for the thought, without being controlled by that thought.  Notice other 
emotions that may emerge other than the urge to breathe.  Survey your entire body and notice 
that, in addition to the urge to breathe, your body contains other sensations and continues to 
function.  Stay with the commitment to hold your breath as long as you can.  As the urge to 
breathe becomes stronger, imagine that you are continuously creating that urge deliberately.  
Close your eyes and see if you can replicate this urge in your imagination, divorced from your 
body.  With every pang in your chest, every worry you have about passing out, shift it from 
something unwelcome that is being visited upon you to something you are creating 
deliberately, just for the sake of feeling what that feels like.  This new urge is formally the 
same, but it is of your creation.  Do you need to be threatened by your own creation?” 
(Eifert & Forsyth, 2005) 
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 Soldiers in the Parade exercise (mindfulness; cognitive defusion) 
o Revisit topic of mindfulness.  Explain goal is to notice internal and 
external events related to HIV and the need to adhere to medication 
prescriptions without imposing judgment (nonjudgmental awareness).  
Note the group will practice noticing and observing internal experiences 
(including perceptual sensations) including, feelings, thoughts, sensations 
(hunger or muscle cramp), and perceptual sensations (what you smell or 
see). This exercise blends simple mindfulness training with cognitive 
defusion to promote acceptance of internal events.  Read the following: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Stress the importance of mindfulness as a precursor to acceptance.  Note it 
is very tempting to try to ignore thoughts related to HIV, particularly 
because they feel “bad.”  Additionally, because of the nature of our minds, 
we are constantly thinking about many different things and can easily 
become sidetracked. 
 
 Wrap-up and homework 
o Session review: The take-home message from the Quicksand metaphor is 
that it is not a lack of effort that’s the problem (as evidenced by his/her 
many attempts to control stresses associated with HIV), but rather the 
fundamental system that does not work, because it cannot work.  Highlight 
the counter-intuitive nature of not struggling with one’s problems.  Note 
willingness to experience events associated with HIV (disclosure, taking 
medications, etc.) takes practice and can be challenging, just like trying to 
 “I’d like us to do an exercise to show how quickly thoughts pull us away from 
experience when we buy them.  All I’m going to ask you to do is to think whatever thoughts 
you think and to allow them to flow, one thought after another.  The purpose of the exercise is 
to notice when there’s a shift from looking from your thoughts, to looking at your thoughts. 
 Imagine that there are little people, soldiers, marching out of your left ear down in 
front of you in a parade.  You are up on the reviewing stand, watching the parade go by.  Each 
soldier is carrying a sign, and each thought you have is a sentence written on one of these 
signs.  Some people have a hard time putting thoughts into words, and they see thoughts as 
images.  If that applies to you, put each image on a sign being carried by a soldier.  The 
soldiers are carrying signs related to HIV, like “You’re HIV+,” “You have to take your 
meds.,” “People won’t want to touch you if they know you have HIV.” 
 The task is simply to watch the parade go by without having it stop and without your 
jumping down into the parade.  You are just supposed to let it flow.  It is very unlikely, 
however, that you will be able to do this without interruption.  And this is the key part of this 
exercise.  At some point you will have the sense that the parade has stopped, or that you have 
lost the point of the exercise, or that you are down in the parade instead of being on the 
reviewing stand.  When that happens, I would like you to back up a few seconds and see 
whether you can catch what you were doing right before the parade stopped.  Then go ahead 
and put your thoughts on the placards again, until the parade stops a second time, and so on.  
The main thing is to notice when it stops for any reason and see whether you can catch what 
happened right before it stopped.  Okay?” 
(Hayes et al., 1999) 
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hold one’s breath.  However, as the AIDS, AIDS, AIDS exercise showed, 
words, thoughts, and feelings, are not necessarily true and do not have to 
dictate or restrict our behavior.  Lastly, note practiced mindfulness will 
help us further recognize and nonjudgmentally observe thoughts and 
feelings associated with HIV. 
o Distribute 10 Valued Domains (values) hand-out 
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Session 3 
 
 (Bring Chinese finger trap to this session.) 
 Introductions and review of group requirements (see Session 1 for details) 
 Review 10 Valued Domains homework (5 minutes) 
o A continued dialogue regarding barriers to medication adherence should 
be initiated. 
o Ask the patient to share one or two domains they rated as personally 
valuable.  Ask patients to explain how living with HIV has interfered with 
these valued domains.  Bring attention to any examples that include 
control strategies and nonacceptance.  For example, a patient may express 
interest in maintaining strong friendships but fear of disclosure has 
interfered with this pursuit.  Connect this to the benefit of being willing to 
experience internal sensations such as fear and how avoiding attempts at 
making new friendships will undoubtedly detract from this value. 
o Some patients may not have completed the homework.  This provides the 
opportunity to examine reasons they did not comply and how this 
resistance may be related to their struggles with medication adherence. 
 HIV-related education  
 Polygraph metaphor (creative hopelessness) 
o Explain this struggle reminds you of an important metaphor.  Begin by 
asking for a volunteer from the group.  Then ask: 
 
 
 
 
 
 
 
 
 
 
 
 
 
o This metaphor allows for the important fact that it is very difficult to 
purposefully control thoughts and feelings, especially when the stakes for 
such control seem high.  With these patients, stress how challenging it is 
to control HIV-related thoughts.  Also note how poor self-management 
behaviors will ultimately have the same consequences as being catapulted 
out the window.  This metaphor illustrates that even when you have every 
incentive to control anxiety you still can’t control your feelings of anxiety. 
 
 Chinese finger trap (acceptance): 
o As a physical metaphor to illustrate the futility of attempting to eliminate 
any distress related to HIV, it is a good idea to bring a Chinese finger trap 
“Suppose I had you hooked up to the best polygraph machine that’s ever been built.  
This is a perfect machine, the most sensitive ever made.  When you are all wired up to it, there 
is no way you can be aroused or anxious without the machine knowing it.  So I tell you that you 
have a very simple task here: all you have to do is stay relaxed.  If you get the least bit anxious, 
however, I will know it.  I know you want to try hard, but I want to give you an extra incentive, 
so I also have a catapult to sit you in.  If you just stay relaxed, it won’t shoot you out the 
window, but if you get nervous (and I’ll know it because you’re wired to this perfect machine), 
I’m going to have to kill you.  Your body will be splattered on the street below.  So, just 
relax!...What do you think would happen?  Guess what you’d get?  Bam!  How could it work 
otherwise?  The tiniest bit of anxiety would be terrifying.  You’d be thinking, “Oh, my God!  
I’m getting anxious!  Here it comes!”  Bam!  You’re dead meat.  How could it work 
otherwise?”  (Hayes et al., 1999) 
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to share with the group.  This allows people to experientially contact the 
impact of trying to struggle out of a problem it is not possible to struggle 
out of, much like HIV.  Explain to the group: 
 
 
 
 
 
 
 
 
 
 
o Distribute the finger trap and allow patients to test this for themselves.  
Highlight how struggling to avoid distress associated with HIV likely 
worsens the experience and exacerbates symptoms.  Common distresses 
will include denial; fear of stigmatization; and discomforts associated with 
taking medications, such as side effects.  Furthermore, it is important to 
connect this discussion to values, emphasizing that struggling with 
experiences can distract one from focusing on a value-driven life and the 
valued domains they examined in this week’s assignment. 
 
 Get off Your But(s) exercise (cognitive defusion) 
o This exercise illustrates how easy it is for patients to get pulled into a 
struggle with their thoughts and feelings.  Unfortunately, patients are 
likely to use “but” many times as a reason for not acting.  This clearly 
restricts their lives and interferes with value-driven behavior.  This little 
change can have a dramatic impact on what might happen next.  This 
simple convention can and should be modeled throughout treatment to 
help illustrate how ingrained this verbal convention can be. 
o Introduce this exercise by first discussing how the patients can increase 
their willingness to take their medications.  Then, as them what will get in 
the way of this pursuit.  Will they fear someone will see them taking the 
medication?  Will they fear the side effects will make the nauseated and 
cause diarrhea?  Will they fear having to face the fact that HIV is a 
chronic disease that will not go away? 
 
o Inevitably, the discussion of barriers will include the word, “but.” For 
instance, “I know I have to take the medications, but, I don’t want people 
to see me taking them.”  Choose one example a patient relates and explain 
the following: 
 
 
 
 
 
 “The situation you are in is something like this Chinese finger trap.  The harder you 
pull, the smaller the tube becomes, and the stronger it holds your fingers.  If the trap is built 
strongly enough, you’d have to pull your fingers out of their sockets to get them out of the 
tube.  Conversely, if you push into it, your finger will still be in the tube, but at least you’ll 
have enough room to move around.  Now, supposed that life itself is like a Chinese finger 
trap.  So, it’s not a question of getting free of the tube, it’s a question of how much “wiggle 
room” you want to have in your life.  If you let go of the struggle, the more freedom you 
have to make new choices.”  (Hayes et al., 1999) 
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o Encourage patients to practice replacing “but” with “and” for the 
remainder of the session.  The therapist can be vigilant to the their use of 
“but” in this way, and can immediately point it out and have the patient re-
phrase the sentence as it occurs.  Revisit some of the barriers to 
medication adherence and ask patients to replace their “buts” with “ands.”  
Ask them if the recognize “but” can be an excuse to not move forward.  
Additionally, can they recognize that two seemingly contradictory 
thoughts can coexist.  Encourage patients to relate this to the practice of 
willingness. 
 
 Wrap-up and homework 
o Session review: The take-home message from the Polygraph metaphor is 
that many times, the harder we try to control something, the worse it gets.  
This certainly applies to trying to control fears associated with HIV by not 
taking one’s medications.  Furthermore, the Chinese Finger Trap exercise 
shows us how struggling not only makes our situation worse, but is the 
exact opposite of what we need to do to solve the problem.  Finally, 
highlight one’s tendency to fall into reason-giving mode, particularly 
when using the word “but.”  These reasons give the false sense that two 
opposing feelings cannot occur at the same time (“I need to take my 
medication and I’m worried about what people will think of me.”).  
However, experience indicates this is not necessarily true.  Therefore, 
patients should be instructed to focus on when they are in reason-giving 
mode, and to see if it is possible to engage in medication adherence and 
feel anxious at the same time (with the help of willingness).   
 
o Distribute Reasons as Causes (cognitive defusion) hand-out 
 The Reasons as Causes hand-out is an exercise in which a patient 
examines his/her reason-giving and evaluates their effects on 
behavior.   It is intended to illustrate the importance of not 
allowing reasons (i.e., verbal constructs) dictate behavior. 
 “This is one thing I want us to use during our work together.  It has to do with our use 
of the word ‘but.’  This is a word that pits one set of thoughts against another.  ‘But’ literally 
means that what follows the word contradicts what went before the word.  For example, this 
morning I thought, ‘I need to get out of bed to go to work, but I would prefer to sleep in.’  See 
how that ‘but’ negated everything I said before it?  The word ‘but’ can be very limiting.  Can 
anyone think of some examples of when they use ‘but?’ (encourage a variety of responses 
and take note of some examples) 
 Now, I’m going to describe a very simple trick to stop ‘but’ from getting in our way.  
Try replacing ‘but’ with ‘and.’  I’ll do it with my example first; instead of saying, ‘I need to 
get out of bed to go to work, but I would prefer to sleep in,’ I said, ‘I need to get out of bed to 
go to work, and I would prefer to sleep in.’  See how that changes things?  Let’s try replacing 
some ‘buts’ with ‘ands’ using the examples you provided.” 
(Eifert & Forsyth, 2005) 
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Session 4 
 
 Introductions and review of group requirements (see Session 1 for details) 
 Review Reasons as Causes homework 
o Encourage patients to share there experiences with reason-giving mode. 
 HIV-related education  
 Feedback Screech metaphor (creative hopelessness) 
o Introduce this metaphor as another example of how attempts to avoid 
experiences associated with HIV not only make the problem worse, but 
also interfere with living a fulfilling life. 
o Ask patients to list the consequences of not adhering to medication at 
proper levels (this should include continued illness, risk of developing 
drug-resistant virus, running out of treatment options due to tolerance, and 
death).  Note that these outcomes clearly will interfere with finding 
personal fulfillment according to valued life domains.  Explain the 
following metaphor as an example of what living in this manner will lead 
to: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o This metaphor emphasizes the unworkability of the control agenda and 
alludes to the importance of living a value-driven life rather than a life 
focused on minimizing psychological pain.  Ask patients if they are 
willing to try something different instead of fearing the feedback.  
Encourage them to envision how their lives would be different if they 
were less focused on controlling and reducing HIV-related stress. 
 
 Passengers on the Bus Metaphor (acceptance) 
o This metaphor relates thoughts and feelings to disturbing passengers on 
the bus, and emphasizes that in trying to control these “passengers,” the 
client has in fact given up control.  Present this metaphor to reinforce the 
need for a new strategy that employs willingness.  Explain: 
“You know that horrible feedback screech that a public address system sometimes 
makes?  It happens when a microphone is positioned too close to a speaker.  Then when a 
person on stage makes the least little noise, it goes into the microphone; the sound comes out 
of the speakers amplified and then back into the mic, a little bit louder than it was the first time 
it went in, and at the speed of sound and electricity it gets louder and louder until in split 
seconds it’s unbearably loud. 
 Your struggles with your thoughts about HIV are like being caught in the middle of a 
feedback screech.  So what do you do?  You do what anyone would.  You try to live your life 
(whispering) very quietly, always whispering, always tiptoeing around the stage, hoping that if 
you are very, very quiet there won’t be any feedback.  You try not to talk about HIV.  You do 
your best to not think about medications or other responsibilities that go along with living with 
the disease.  (Normal voice) You keep the noise down in a hundred ways: drugs, alcohol, 
avoidance, withdrawal, etc.  The problem is that this is a terrible way to live, tiptoeing around.  
You can’t really live without making noise.  But notice in this metaphor, it isn’t how much 
noise you make that is the problem.  It’s the amplifier that’s the problem.  Our job here is not 
to help you live your life quietly, our job is to find the amplifier and to take it out of the loop.”   
(Hayes et al., 1999) 
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o Summarize the exercise by noting that in constantly trying to deal with 
people on the bus, you are constantly getting pulled off your path.  
Emphasize how this detracts from following one’s chosen path and that 
trying to make thoughts and feelings go away keeps one from moving 
forward.  Also explain that driving this bus is about healthy HIV-related 
behavior.  Be vigilant to recognizing patients who believe the only way to 
continue on the path is to get rid of urges, OR who are fused with the 
mentality that these things cannot actually influence behavior and/or be 
derailing.  
 Be Where You Are (mindfulness) 
o This exercise encourages mindful attention and can be connected to the 
need for mindfulness in the pursuit of developing willingness to 
experience sensations associated with living with HIV.  Ask patients to 
describe how they typically feel when they are in a situation where they 
may need to disclose their HIV status.  How do they respond to those 
feelings?  Can they connect these reactions to their pursuit (or lack 
thereof) of value-driven living? 
o Explain this exercise is intended to help hone their mindfulness skills.  
Remind patients as they participate in this exercise not to panic if their 
mind starts to wander.  Instead, encourage them to bring themselves back 
to the present moment and continue to follow your instructions.  
Encourage the patients to sit comfortably in their chairs, to close their 
eyes, and to take a few deep breaths.  Explain this exercise may be 
relaxing but that its primary purpose is to promote mindfulness.  Read the 
following instructions: 
 
 
 
 
“Let’s pretend that I’m up here driving a bus down the living well with HIV highway 
(stand up and turn your back to the group) and let’s pretend that you are the passengers in the 
back of the bus who represent distressing things that you have to go through as you’re trying 
to live with HIV. For example, one of you may say this is too hard to keep track of the pills or 
another one may say the side effects are too painful. While I’m driving the bus I want you to 
be out loud saying these things. (Encourage everyone to list their complaints. Everyone starts 
saying things and then the bus driver gets up and argues with different people).  What 
happened?  Did you notice any problems with what I was doing?  See how easy it is to get off 
track? 
Let’s try it for a second time.  What’s a different way of responding: to drive the bus 
and continue. (Begin metaphor again and encourage patients to vocalize their complaints.  
Let passengers know that you weren’t ignoring their voices.  I definitely heard you guys, 
sometimes it was uncomfortable, you really annoyed me, it was unpleasant, I can’t pretend 
that you guys aren’t there.) Did you think that was easy for me? No, it wasn’t easy for me it 
was really.  It was distressing, distracting, and I felt discouraged at times but I knew that I 
didn’t want to get off track.”  (Hayes et al., 1999) 
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o Solicit patients’ experiences, particularly inquiring about their success at 
staying mindful and catching themselves when they became distracted.    
Emphasize the fact that mindfulness is a skill that requires practice and 
that you will give them a hand-out to practice this exercise at home. 
 
 Wrap-up and homework 
o Session review: Inevitably, we get stuck trying to tiptoe around, focusing 
our efforts on avoiding any chance of experiencing something negative, 
like the feedback screech discussed at the beginning of this session.  Ask 
patients to connect this metaphor to the Passengers on the Bus metaphor, 
to illustrate the connection between pursuing values and defusing from 
internal and external experiences.  Stress the importance of mindfulness 
practice as a means of improving willingness skills. 
o Distribute copies of extended Be Where You Are cassette/CD 
 
 “Now slowly bring your awareness to the tips of your fingers.  Feel your fingers.  
Rub your fingertips together.  How do they feel?  Can you feel the small indentations on 
your fingertips that are your fingerprints?  Take your time and try to feel them.  What are 
they like?  Are your fingertips rough from lots of work or are they smooth and silk?  
Notice these feelings and move on. 
 Now rest your fingers where they were before.  What are they touching?  What 
does that feel like?  Is it soft or hard?  Does it have any other distinguishing features?  
Take the time to completely absorb the way these objects feel to your fingertips. 
 Now bring your attention to your hands and arms.  What do they feel like?  
Perhaps they are relaxed and heavy.  Perhaps they are still tense from a long day’s work.  
Either way is okay.  There is no need to judge, simply observe the feelings in your arms 
and hands.  Are there any aches or pains?  Take note of these but do not fixate on them.  
Simply note the pain and move on. 
 What about your face?  How does your face feel?  There are all kinds of 
sensations to explore in your face.  Think about your brow.  Is it smooth and flat or is it 
crinkled up with stress?  Again, don’t try to change it, just notice it.  Now bring your 
awareness to your nose.  How does that feel?  Can you feel cool air flowing into your 
lungs or is the air warm?  Pay attention to the feeling for a moment.  Then think about 
your mouth.  How is your mouth positioned?  Is it pursed?  Is it open?  Is it closed?  
What about the inside of your mouth?  Is it wet or dry?  Can you feel your saliva coat the 
inside of your mouth and throat?  Explore all of the sensations throughout your face.  
Perhaps you can feel oil on your skin. Perhaps your skin is dry.  Perhaps there is no 
feeling at all.  Just note it and move on. 
 Now think about the room you are in.  Where are you positioned in the room?  
Do you have a sense of where the door is?  What about the ceiling?  Can you feel your 
body in the context of this larger space? 
 When you are ready, open your eyes and take a look around the room.”  (Eifert 
& Forsyth, 2005) 
 
 101 
Session 5 
 
 Introductions and review of group requirements (see Session 1 for details) 
 Review homework 
o Some patients may not have completed the homework.  This provides the 
opportunity to examine reasons they did not comply and how this 
resistance may be related to their struggles with medication adherence. 
 HIV-related education 
o Because this is the final session, metaphors should be presented as final 
refreshers to solidify understanding of important points.  Nearly half the 
session can be devoted to post-treatment planning. 
 Playing Volleyball metaphor (creative hopelessness) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o The take-home message is that it is not a lack of effort that’s the problem 
remains, but rather the fundamental system that does not work, because it 
cannot work.  Ask the group if they can think of any metaphors that 
illustrate this same point. 
 
 Hungry Tiger (acceptance) 
o This example provides another perspective on willingness and links it to 
experiential avoidance.  Read the following example: 
 
 
 
 
 
 
 
“Throughout a volleyball match, both teams strive to keep the ball in action, back 
and forth from one side of the court to the other and never letting the ball hit the ground.  
Each player stands alert and ready, trying to read the opponents in anticipation of their next 
move.  The strategy of volleyball is a way of describing how you are responding to your 
distressing thoughts and feelings.  Imagine that a volleyball match is going on inside your 
mind.  Instead of volleying a ball back and forth, the teams inside your head are volleying 
thoughts about you.  Much like competitive volleyball, your distressing experiences seem 
intense and forceful.  And just when you thought they might be taking a rest, they are right 
back in your face, challenging you and yelling at you to take them on. 
 On one side of the court is Team D (Distress).  Team D serves up the following 
thought: If you keep your HIV pills with you during the day, someone is going to find out 
you’re HIV+. This could get you into a lot of trouble! 
 Team S (Struggle) is ready for action, diving to the ground to prevent that thought 
from touching the ground: Wait a minute.  I need my medications with me and people 
probably won’t find out. 
 And so the game goes on and on.  As soon as Team Distress serves up an unsettling 
thought, Team Struggle responds to that thought by somehow arguing with it.  Have you 
noticed how this volleyball competition of thoughts and feelings seems to go on in your 
head?”  (Eifert & Forsyth, 2005) 
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 Wrap-up and homework 
o Post-treatment planning 
 Discuss patients thoughts and feelings related to concluding 
treatment/no longer attending workshops. 
 Ask patients to volunteer information regarding what has resonated 
with them in these workshops and instruct them to focus on those 
elements as they move forward in their lives. 
 Distribute post-treatment plan worksheet to patients before the 
conclusion of the session. It encourages patients to organize their 
future plans in a step-wise manner, beginning with general values, 
then formulating long-term goals to help them work towards these 
values, and finally, short-term goals that are modest in scope and 
can be realistically achieved.  This emphasizes the relationship 
between goals and values: values are long-term directions we 
move towards and goals are the steps that keep us on the path. 
 
 
 
  
“Imagine you wake up one morning and just outside your front door you find an 
adorable tiger kitten mewing.  Of course you bring the cuddly little guy inside to keep as a pet. 
After playing with him for a while, you notice he is still mewing, nonstop, and you realize he 
must be hungry.  You feed him a bit of raw ground beef knowing that’s what tigers like to eat.  
You do this every day, and every day your pet tiger grows a little bigger.  Over the course of 
two years, your tiger’s daily meals change from hamburger to prime rib to entire sides of beef.  
Soon your little pet no longer mews when hungry.  Instead, he growls ferociously at you 
whenever he thinks it’s mealtime.  Your cute little pet has turned into an uncontrollable, savage 
beast that will tear you apart if he doesn’t get what he wants. 
 Your struggle with your frustrations about HIV can be compared to this imaginary pet 
tiger.  Every time you empower your pain by feeding it the red meat of experiential avoidance, 
you help your pain-tiger grow a little bit larger and a little bit stronger.  Feeding it in this 
manner seems like the wise thing to do.  The pain-tiger growls ferociously telling you to feed it 
whatever it wants or it will eat you.  Yet, every time you feed it, you help the pain to become 
strong, more intimidating, and more controlling of your life.” 
(Eifert & Forsyth, 2005) 
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